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ABSTRACT OF THE DISSERTATION 
 
Microglial Contributions to Alzheimer’s Disease Pathogenesis 
 
By 
 
Elizabeth Erin Dominguez 
 
Doctor of Philosophy in Biological Sciences 
 
 University of California, Irvine, 2019 
 
Associate Professor Kim Green, Chair 
 
 
 
Microglia are the primary central nervous system (CNS) immune cell and carry out a 
variety of important functions in the brain, including immune defense, regulation of 
synaptic formation and maintenance, promotion of proper brain connectivity, calcium 
homeostasis, and trophic support for neurons. Increasing evidence points to a loss of 
microglial homeostatic functioning in disease conditions, including Alzheimer’s disease 
(AD), leading to the hypothesis that a failure in immune-related mechanisms contributes 
to disease progression. Additionally, genome-wide association studies (GWAS) identify 
variants in myeloid-associated genes as a substantial contributor to AD risk, highlighting 
the significance of myeloid biology in the development of AD. Thus, intense focus has 
recently been placed on microglia to identify their roles in AD onset and progression. 
Importantly, the development of compounds and genetic models to ablate the microglial 
compartment have emerged as effective tools to further our understanding of microglial 
function in AD. Previously, we reported that administration of colony-stimulating factor 1 
receptor (CSF1R) inhibitors eliminate >99% of microglia brain-wide in the healthy adult 
murine brain. As an extension of these findings, the goal of my dissertation is to utilize 
xii 
 
CSF1R inhibitors in mouse models of Alzheimer’s disease to ascertain the various 
function(s) of microglia in AD pathogenesis. As demonstrated in the first chapter of my 
dissertation, I administered CSF1R inhibitors to mice to ablate the microglial 
compartment for one month during advanced stages of pathology in 5xfAD mice, of 
which 12% of plaque-distal microglia survived CSF1R inhibitor treatment whereas 50% 
of plaque-associated microglia remained. With this paradigm, I observed improvements 
in contextual fear memory, normalized brain-wide inflammatory signaling, the 
regeneration of lost dendritic spine densities, and additionally, the absence of microglia 
prevented neuronal loss. These data indicate that, during the later stages of disease, 
primarily plaque-distal microglia mount a detrimental and non-resolving inflammatory 
response in the AD brain that damages synapses and neurons, ultimately impairing 
cognitive function, whereas plaque-associated microglia exert neuroprotective effects. 
Importantly, microglial ablation in advanced pathology AD mice did not modulate -
amyloid (A) burden in the brain, possibly due to a loss of microglial A clearance 
capabilities during advanced stages of AD. As previously stated, myeloid biology is 
heavily implicated in the development of AD, via GWAS; thus, I next sought to explore 
the contributions of microglia in disease onset. To that end, I eliminated microglia prior 
to the onset of pathology, as well as throughout the course of disease in chapter two. As 
microglia are phagocytic cells, if the degradation of A by microglia in early AD protects 
against A accumulation and deposition, perturbing this process while microglia are 
functional phagocytes should dramatically elevate A pathology. Contrary to 
expectations, I found that lifelong ablation of microglia prevented parenchymal plaque 
burden, except in areas where microglia survived CSF1R inhibition, indicating that 
xiii 
 
microglia are facilitate plaque formation. In chapter three of the dissertation, I expanded 
upon these findings and identify microglial Apolipoprotein E (ApoE) as a contributor to 
plaque formation in 5xfAD mice. Collectively, these results highlight a spectrum of 
microglial functional states, dependent on disease stage (i.e., A pathology onset and 
disease severity) and proximity to A plaques, and demonstrate that microglia act as 
critical and causative agents in the onset and development of AD pathology. 
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INTRODUCTION 
A. Alzheimer’s disease pathophysiology 
Sporadic AD is an age-related, neurodegenerative disease characterized by the 
extracellular deposition of Aβ plaques and intraneuronal tau neurofibrillary tangles. It is 
one of the most common forms of dementia, affecting roughly 10% of the population 
aged 65, and up to 50% of people aged 85 and over1, with the number of cases 
expected to triple by 20502. Therefore, understanding the mechanistic changes in the 
human brain leading to pathophysiology of the disease is essential to produce effective 
therapies. According to the amyloid cascade hypothesis, the triggering factor for the 
disease is the accumulation of amyloid aggregates composed of Aβ peptides3. A critical 
role of Aβ in AD manifestation is supported by mutations in -amyloid precursor protein 
(APP) and presenilin 1 (PSEN1) and presenilin 2 (PSEN2) that lead to increased Aβ 
production and deposition in familial AD4. In sporadic AD, Aβ may have an initiating role 
and is implicated in a complex network of pathological processes, including sustained 
chronic neuroinflammation, tau hyperphosphorylation, synapse degeneration and 
neuronal loss. These processes may converge over time, until neurodegeneration 
prevails and clinical symptoms manifest5. This progression has been divided into three 
stages: preclinical, mild cognitive impairment (MCI), and dementia6. Following amyloid 
deposition, the presence of intraneuronal neurofibrillary tangles comprised of 
hyperphosphorylated tau is observed, which correlates more strongly with cognitive 
status, and neurodegeneration, than amyloid pathology7.  
Due to the general acceptance of the amyloid cascade hypothesis since its conception, 
the field of AD has historically been driven toward developing A-modulating 
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therapeutics. Indeed, amyloid deposits in humans present decades before the cognitive 
deficits associated with this disorder are evident8. However, to date, all therapies 
designed to modulate A production in the AD brain have failed in the clinic, as well as 
the vast majority of non-A-targeting therapies9. Thus, AD has one of the highest failure 
rates of any disease at 99.5-99.6%9. These failures were presumably due to attempts to 
intervene at later stages in the disease process when substantial neuronal loss has 
already occurred, suggesting that treatments during the prodromal or MCI stages of AD 
may be beneficial. However, A-targeting therapeutics administered during these 
phases have proved ineffective, as evidenced by the recent failure of Biogen’s Phase III 
clinical trials of aducanumab, administered during the early symptomatic phase of AD 
(unpublished results from ADPD Conference, 2019). Thus, a reevaluation of the precise 
roles of various pathologies in AD is required and highlights a need for AD treatments to 
extend beyond the realm of A modulation.  
 
B. Microglial roles under homeostatic conditions 
Microglia are the brain’s resident immune cells, comprising approximately 10-15% of all 
cells found in the brain10, whereby they function as the first line of defense to protect the 
CNS from injury and invading pathogens. In this surveying state, microglia exhibit a 
ramified morphology and support the health and functioning of neurons. Upon detection 
of an insult, microglia respond by becoming activated, developing an amoeboid 
morphology, and migrating to, and proliferating at, the site of the insult. In acute 
inflammatory events, the pro-inflammatory response resolves and microglia continue 
their surveillance of the brain parenchyma and maintenance of synaptic and neural 
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circuitry. In the following sections, I will briefly outline the various roles of microglia in 
the healthy brain, highlighting specifically their roles in immune surveillance, pathogen 
recognition and injury response, and synaptic and circuit sculpting.  
 
CNS maintenance and immune surveillance 
Disturbances in homeostasis result in an immune response mediated by microglia, 
distinguished by dramatic morphological, functional, and transcriptional alterations of 
these cells11-13. This state of microglial activation coincides with a reorganization of 
surface receptors to facilitate interactions between extracellular molecules and 
neighboring cells and release of soluble factors that act as pro- or anti-inflammatory 
mediators. Activated microglia produce and secrete several proinflammatory mediators, 
including tumor necrosis factor-⍺ (TNF⍺), interleukin (IL)-6, and nitric oxide (NO), all of 
which play a role in cellular debris and pathogen clearance14. Neuroimmune regulatory 
proteins modulate the immune response and facilitate the resolution of inflammatory 
processes15, which subsequently leads to the activation of neurotrophic signaling 
pathways that promote tissue repair, including insulin-like growth factor 1 (IGF-1), brain-
derived neurotrophic factor (BDNF), transforming-growth factor-β (TGF-β), and nerve 
growth factor (NGF)16. The resolution of the inflammatory response is essential for CNS 
homeostasis, with failures in normal inflammation resolution mechanisms leading to a 
chronic neuroinflammatory state and progression of neurodegenerative changes17.  
 
Injury response and pathogen detection 
While in a quiescent state, microglia are continually active and surveying the brain 
environment, extending and retracting their processes without disturbing the fragile 
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neural circuitry18. However, following minimal alterations to brain homeostasis, microglia 
readily undergo activation-related processes19. This can involve phagocytic processes, 
whereby microglia utilize their highly developed lysosomal compartment that bears 
critical protease activity to remove tissue detritus or damaged cells20-24. Microglia 
constitutively express several families of receptors that facilitate the removal of aged, 
necrotic tissues, and toxic molecules from the circulation and their surroundings. Among 
these receptors are scavenger receptors (e.g., CD36, SR1)25,26, low-density lipoprotein 
(LDL) receptor family members (e.g., LDLR, ApoER2, and VLDL)25,26, and three 
receptor tyrosine kinases (i.e., the TAM receptors Tyro3, Axl, and Mertk)27. In addition, 
microglia capture and endocytose immune complexes and complement-opsonized 
protein complexes through Fc receptors28 and complement receptors24,29, including CR1 
(CD35), CR2 (CD21), CR3 (CD11b, CD18), CR4 (CD11c, CD18), and C5aR (CD88, 
C5L2). To regulate migration and positioning of microglia in the CNS and to enhance 
their phagocytic functioning, microglia also express chemokine receptors30, such as 
CX3CR1 and CXCR4 and integrins (e.g., CD11b and CD11c). As stated earlier, 
microglia return to a quiescent state to continue homeostatic maintenance functions 
following stimulus removal from the brain.  
 
 
Synaptic sculpting and cognition 
In addition to clearance of cellular debris and pathogens, microglia are involved in the 
removal of synapses from neuronal cell bodies via synaptic stripping. This phenomenon 
was first observed in a model of facial nerve injury in rats31, in which microglial 
localization to the site of injury and interaction with facial motor neurons resulted in the 
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removal of synaptic contacts. In the developing brain, microglia form brief, repetitive 
contacts with synapses, eliminating any weak or unnecessary synaptic structures, a 
process which is modulated by sensory experiences22. Knockout of the microglial 
purinergic receptor P2Y12, which mediates process motility during injury response, also 
disrupts plasticity in the visual system32. While the exact mechanism behind microglia-
mediated synaptic elimination (whether it be by phagocytosis or the secretion of various 
factors) has yet to be elucidated, it is evident that the interaction between microglia and 
synapses is crucial for activity-dependent plasticity in the developing brain. 
Accumulating evidence points to neuron-microglia crosstalk as an essential mechanism 
for proper synapse and network maintenance. One pathway implicated in this crosstalk 
involves CX3CR1 expressed on microglia and its ligand CX3CL1, released by neurons. 
Knockout of CX3CR1 during development produces deficits in synaptic pruning, 
characterized by an excess of dendritic spines and immature synapses, resulting in 
weakened synaptic transmission and decreased functional brain connectivity20. 
Behaviorally, loss of CX3CR1 manifests in impaired social interactions reminiscent of 
autism spectrum disorder and other neuropsychiatric disorders20. While increasing 
evidence points to critical roles of microglia in synaptic maintenance, investigations into 
the functional significance of these events were scarce. Using electrophysiological 
approaches, it was demonstrated that a reduction in synapses restricted the frequency 
of glutamatergic synaptic currents33, suggesting that microglia influence neuronal 
communication and function. Furthermore, disruption of signaling between complement 
3 (C3), which is localized to synaptically-enriched regions, and its receptor, complement 
receptor 3 (CR3), impairs microglial phagocytosis of synaptic inputs, leading to 
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sustained deficits in brain wiring34. Collectively, these studies underscore the role of 
microglia as regulators of the synaptic landscape in the developing brain, implicating 
neuron-microglia crosstalk as a crucial process for proper brain development.  
The role of microglia in synaptic sculpting during development is well-described, and we 
previously reported that the absence of microglia in the healthy adult mouse brain 
increases total dendritic spine density and intensity of immunolabeling for the synaptic 
surrogates PSD95 and synaptophysin35,36, indicating that microglia continue to regulate 
the synaptic landscape in adulthood. Collectively, these studies point to microglia as 
critical mediators of synaptic sculpting in the developing and adult brain, providing a 
vital function in shaping and modulating neuronal circuitry to maintain normal brain 
connectivity. 
 
C. Microglial dysfunction in Alzheimer’s disease 
GWAS and myeloid biology in AD 
The hypothesis of compromised microglial function as a contributor to AD pathogenesis 
gained momentum following the publication of recent GWAS results. These studies 
identified several single nucleotide polymorphisms (SNPs) that convey risk of 
developing AD, with many of these SNPs associated with or related to microglial 
function including triggering receptor expressed on myeloid cells 2 (TREM2), CD33 
molecule (CD33), complement receptor type 1 (CR1), clusterin (CLU), EPH Receptor 
A1 (EPHA1), ATP-binding cassette transporter A7 (ABCA7), SPI1, and inositol 
Polyphosphate-5-Phosphatase D (INPP5D)37-39, indicating that microglia play a critical 
role in the development of AD. The generation of knockout mice for various immune-
associated GWAS genes have allowed for in vivo investigations into the contribution of 
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these genes in AD pathogenesis. Inactivation of CD33 in APP/PS1 mice reduced A 
accumulation and plaque burden40, whereas ABCA7 deficiency in APP/PS1 and 
TgCRND8 mice exacerbated A load41,42, highlighting the importance of these genes in 
regulating A pathology. Additionally, reports of TREM2 deficiency in AD mice found 
worsening43 and mitigation44 of A pathology. This discrepancy in plaque observations 
was later found to be related to disease progression, whereby TREM2 deficiency 
ameliorates plaque burden in early AD and exacerbates plaque pathology in later 
stages45. However, a common thread throughout all TREM2-knockout studies is the 
prevention of the association of myeloid cells – whether it be microglia or monocytes – 
with plaques, indicating that TREM2 signaling regulates myeloid cell responses to A in 
AD. 
 
Immune activation in plaque formation processes 
In addition to the general functions of these cells in AD, the timing of neuroinflammation 
in the progression of AD is also crucial to our understanding of the disease – reports 
indicate that inflammatory changes precede the appearance of amyloid plaques46-48. In 
line with observations in humans, early immune activation in AD mice can trigger 
disease pathogenesis. Specifically, systemic immune stimulation in prenatal mice with a 
viral mimetic (i.e., double stranded RNA) followed by immune challenge later in 
adulthood, was sufficient to induce the development of sporadic-like AD, characterized 
by deposition of Aβ and tau, impairments in working memory, as well as chronic 
microglial activation49. Interestingly, this study provides evidence for immune activation 
early in life as a sufficient factor to induce AD onset. In support of immune mechanisms 
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driving disease initiation, it was recently demonstrated that microglia release apoptosis-
associated speck-like protein containing a CARD (ASC) specks in an age-dependent 
manner through the activation of the NACHT-, LRR-, and pyrin-domain-containing 
protein 3 (NLRP3) inflammasome in AD50. In vivo, ASC specks form in response to A 
and their release following microglial activation enhanced A seeding and spreading50, 
suggesting a mechanism by which physiological microglial activity contributes to plaque 
formation. However, PET imaging with the second generation TPSO ligand DPA-714 in 
early stage and prodromal AD patients showed that patients with increased ligand 
binding exhibited slowed cognitive decline, suggesting that microglial activation is 
protective in the early stages of the disease51. Collectively, these studies – in addition to 
the TREM2 studies discussed earlier – highlight the importance of inflammation-
targeted therapeutic approaches for treating AD, but caution that the timing of 
intervention may be crucial.  
 
Neuroinflammation in AD 
Within the CNS, immune-related responses are encompassed by the term 
neuroinflammation, which influences both cellular and tissue homeostasis and supports 
neuronal functioning52. Under normal physiological conditions/non-disease states, 
neuroinflammatory processes are self-limiting, resolving once the detected stimulus is 
cleared from the brain. This acute form of neuroinflammation is in stark contrast to the 
chronic form observed in AD (Fig. 1), which is hypothesized to result from a failure in 
immune clearance mechanisms53,54. Neuroinflammation is a complex process that 
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involves various cell-cell interactions within the CNS55. Microglia and astrocytes are the 
two types of glial cells with distinct etiologies that contribute to the initiation of the 
inflammatory cascade56,57.  The perception of pathological triggers, such as A in AD, is 
mediated by receptors originally designed to recognize danger- or pathogen-associated 
molecular patterns (DAMPs/PAMPs)58-60. Following stimulus recognition, glial cells 
produce and secrete various proinflammatory cytokines, as well as a number of 
chemokines that facilitate the recruitment of additional glial cells14. Indeed, exposing 
microglia to Aβ induces the production and release of pro-inflammatory  cytokines, 
including IL-1β, IL-6, TNFα, TGF-β, as well as chemokines, such as macrophage 
Figure 1 Acute versus chronic activation of microglia in AD. Aβ binds to PRRs, leading to 
activation of resting microglia. Acutely activated microglia express cytokines, which drive enhanced 
phagocytosis, uptake, and clearance of Aβ. Long-term activation of microglia drives proliferation as 
well as a chronic inflammatory state that causes neurotoxicity and neurodegeneration. Sustained 
activation of microglia, induced by brain trauma, systemic inflammation, obesity, and reduced 
physical activity, also drives neurotoxicity and neurodegeneration. DAMPs that arise from these 
processes further activate microglia, leading to compromised Aβ phagocytosis and propagating 
chronic inflammation. Chronic inflammation and accumulation of Aβ are well-established clinical 
features of AD. 
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inflammatory proteins (MIP)-1a, 1b, -2, and C-C motif chemokine ligand 2 (CCL2)14, 
presumably in an attempt to facilitate the clearance of Aβ. Collectively, the production of 
these pro-inflammatory mediators can promote the neurodegeneration of otherwise 
healthy neighboring neuronal populations14. While undergoing cellular death, these 
neurons release their cellular contents and secrete DAMPS, amplifying and 
perpetuating the inflammatory response61,62. Many of the highly upregulated neurotoxic 
factors in the AD brain are evidenced to be microglia-derived, including TNF-α, NO, IL-
1β, and reactive oxygen species (ROS)63. Moreover, the secretion of IL-1, TNF-, and 
C1q by microglia was demonstrated to induce astrocyte reactivity, which in turn 
promoted the death of neurons and oligodendrocytes64, further emphasizing the 
detrimental effects of factors secreted by chronically-activated microglia. Additionally, 
knockout of Nlrp3 – a critical component in the inflammasome pathway and major 
contributor to neuroinflammatory insult in the CNS – mitigated inflammatory signaling, 
decreased deposition of Aβ, restored synaptic plasticity, and improved cognitive 
function in APP/PS1 mice65. Importantly, the formation and secretion of the NLRP3 
inflammasome is restricted to the microglial compartment in the mouse brain66, which 
together with the Nlrp3 knockout data, indicates that dysfunctional regulation of 
microglial NLPR3 signaling may contribute to plaque onset in AD.  
In AD, neuroinflammation is considered a chronic and detrimental process67. Post-
mortem examination of AD brains consistently demonstrates elevated numbers of 
microglia and astrocytes surrounding A deposits68. This observation is accompanied 
by overall increases in inflammatory cytokine and chemokine production68. Additionally, 
the extent of gliosis correlates strongly with disease progression and cognitive 
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impairments69,70 with data suggesting that microglia are the critical cell type contributing 
to this neuroinflammatory environment in AD71, leading to increased interest in 
understanding the function of microglia-mediated neuroinflammation in AD. 
 
Microglial phagocytosis and clearance of aggregated Aβ  
Since microglia are the primary immune cell in the brain and A accumulation has been 
implicated as a causative factor in AD, intense focus has been placed on the regulation 
of A dynamics by glial cells. The clearance of A by glial cells is carried out through 
the following primary mechanisms: 1) production of various A-degrading proteases 2) 
activation of glial proteasomal and autophagic pathways, 3) glial 
internalization/degradation of A and 4) secretion of extracellular chaperones that 
facilitate the exit of A to the periphery. For the production of A-degrading proteases, 
glial cells are responsible for the expression of the vast majority of these factors72. The 
metalloendopeptidases neprilysin and insulin degrading enzyme (IDE) degrade primarily 
monomeric A species73,74, whereas plasminogen activators and angiotensin-converting 
enzyme (ACE) are more effective at degrading aggregated A. Matrix metalloproteases 
(MMPs) are involved in the degradation of both monomeric and fibrillar forms of A. 
Lastly, lysosomal peptidases including Cathepsin B are involved in the degradation of 
A following its phagocytosis by microglia, in part by reducing longer forms of A into 
shorter, less toxic species, such as A1-3875. In the ubiquitin proteasome system (UPS), 
individual target proteins, including damaged, short-lived, or misfolded proteins are 
selectively targeted by the conjugation of ubiquitin76, which is performed by several 
enzymes (E1-3). Indeed, the UPS is capable of cleaving A in a dose-dependent 
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manner77 and E3 ligases play a crucial role in the degradation of A. In the autophagy 
pathway, it is proposed that defective clearance of A-generating autophagic vacuoles 
creates a favorable environment for the accumulation of A in AD. In support of this, 
increasing autophagic processes via rapamycin reduces amyloid burden in vivo78. 
Additionally, extracellular chaperones play a pivotal role in the clearance of A through 
their modulation of A fibrils and mediation of interactions between A and lipoprotein 
receptor related protein 1 (LRP1) receptors on astrocytes. Genetically, the E4 allele of 
the apolipoprotein E gene is the strongest risk factor for sporadic AD, with the presence 
of one allele sufficient to increase an individual’s risk for developing AD ~3-4 fold79. 
Thus, ApoE is easily the most studied of the extracellular chaperones. While 
predominantly expressed by astrocytes, ApoE expression can be induced under 
disease conditions in microglia80,81 and is highly enriched in plaque-associated 
microglia82,83. As a chaperone, ApoE binds A in an isoform-dependent manner, with 
reduced A-ApoE binding in the presence of the ApoE4 isoform84, leading to increased 
seeding of fibrillar A and transport of soluble A. Another important mechanism of A 
clearance is its internalization by microglial cells. A can be internalized and cleared by 
microglia through fluid phase pinocytosis85, phagocytosis, particularly when bound by 
the C3b complement system86, and receptor-mediated endocytosis via action of 
Scavenger receptors58,87, Toll-Like receptors88, Receptor for Advanced Glycation End 
Products (RAGE)89, Fc Receptors90, TREM243,91, and LRP192. Thus, microglia regulate 
A clearance through a variety of mechanisms, many of which go awry in AD.  
Traditionally, it was believed that microglia respond to the presence of Aβ deposits by 
clearing them from the brain via phagocytosis of Aβ-fibrils93. In vitro studies show 
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accumulating evidence that microglia internalize and degrade Aβ aggregates94-98. 
However, there has been no clear consensus in vivo as to whether microglia are 
capable of phagocytosing and degrading Aβ, as some studies show internalization of 
Aβ within the microglial lysosome99 whereas others observe no Aβ plaque clearance by 
these cells100,101. To directly assess the roles of microglia in A clearance and plaque 
dynamics, several methods for in vivo microglial ablation have been developed, allowing 
researchers to probe the contribution of microglia to pathophysiology. For example, 
clodronate liposomes induce apoptosis in phagocytizing macrophages102. Using this 
method in P0 5xfAD mouse organotypic hippocampal slice cultures, microglial depletion 
leads to the rapid accumulation of A deposits, showing that microglia in development 
and/or in slice cultures actively clear A94. However, upon replenishment with juvenile 
microglia, A clearance is restored resulting in fewer A deposits. Notably, 
replenishment with adult 5xfAD microglia does not reduce plaque deposits, indicating 
that the phagocytic ability of microglia is quickly lost with age, somewhere between 1 
and 6 months of age. In CD11b-HSVTK mice, the thymidine kinase of herpes simplex 
virus is expressed under the CD11b promoter. Thymidine kinase converts ganciclovir 
into cytotoxic kinases, leading to cell death of CD11b-expressing cells (i.e., microglia in 
the CNS) and can maintain ablation for up to four weeks103. In these investigations, 
researchers crossed CD11b-HSVTK and AD mice to assess alterations in plaque 
dynamics with the elimination of microglia and found no changes in plaque load, Aβ 
levels, or dystrophic neuritic structures near plaques, in either young or aged animals104. 
As the absence of microglia had no impact on Aβ dynamics, these data suggest that 
aged microglia may not be actively involved in phagocytosing and/or clearing plaques in 
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the AD brain. Collectively, it appears that microglia in AD are ineffective A phagocytes, 
as evidenced by the continued presence of plaques surrounded by activated microglia 
in the AD brain, contributing to the enduring chronic neuroinflammatory environment for 
the duration of the disease. 
Recent evidence suggests that plaque-associated microglia in vivo are in a suppressed 
phagocytic state due to the overproduction of IL-10105, prostaglandin E2 (PGE2)106, and 
arginase-1107. Indeed, subsequent exposure of microglia to certain stimuli, including 
lipopolysaccharide (LPS)108, IL-1β109, IL-33110, as well as the retinoid X receptor agonist 
bexarotene111, 40Hz light stimulation112, ultrasound113, and 40 Hz auditory stimulation114 
are sufficient to induce microglial degradation of Aβ. Together, these studies indicate 
that microglia are fully capable of Aβ phagocytosis, given a favorable environment in 
which to do so. Additionally, in a transgenic model of Aβ arrest, switching off the APP 
transgene halted the progression of Aβ pathology, but did not induce the breakdown or 
clearance of plaques115, providing further evidence that microglia are not responsible for 
regulating A dynamics in the AD brain.  
 
Neuroprotective functions of microglia in AD 
Although the evidence implicating microglial association with plaques is pervasive in 
different murine models of AD, as well as AD patients, the function of this association is 
still under investigation. Through examination of the role of microglia in regulating 
plaque dynamics, it was discovered that microglia constitute a barrier surrounding 
amyloid deposits, serving to limit the outward expansion of Aβ deposition91,116-118. 
Moreover, plaque-associated microglia limited the toxic effects of Aβ42 hotspots on 
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nearby neurons117. As smaller (and presumably newer) plaques were most restricted in 
size, these data provide evidence for a neuroprotective role of microglia early in the 
disease in shielding neurons from toxic species of Aβ and suggests that this method of 
plaque restriction is lost with age. Indeed, recent evidence describes a specific 
expression profile of plaque-associated microglia in the AD brain, identified as disease-
associated microglia (DAM)83, which are neuroprotective and switched on during 
disease. This neurodegenerative phenotypic switch is triggered by TREM2, leading to 
activation of APOE signaling and subsequent suppression of homeostatic microglial 
phenotype83,119. DAM cells express Spp1, Itgax, Axl, Lilrb4, Clec7a, Csf1, and Apoe and 
are highly enriched in microglia surrounding plaques83,119. Because of their association 
with plaques and increased intake of A particles, it is postulated that DAM cells are a 
more phagocytic subset of microglia. In support of this, knockout of Trem291 and 
Apoe118 increased plaque-associated neuritic dystrophy, highlighting the beneficial 
effects of this subset of microglia in the AD brain. Thus, more effective treatments for 
AD may involve designing targets for specific subsets of microglia – modulating the 
function of microglia in plaque-distal areas that may be involved in A seeding, but 
preserving subsets of neuroprotective microglia that are plaque-proximal.  
Collectively, numerous studies implicate microglial reactivity in AD pathogenesis, but 
point to dichotomous roles of microglia throughout the disease course. In earlier stages 
of AD, many reports suggest that microglial phagocytosis and clearance of A is crucial 
to curtail disease progression; however, recent evidence suggests that microglia may 
contribute to the appearance of plaques in the AD brain. Once plaques appear in AD, 
microglia exert neuroprotective functions by encapsulating plaques with their processes 
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and cell bodies, limiting the interaction of toxic A species with nearby neurons. In 
contrast to this, microglia in advanced stages of AD fail to clear A from the brain, 
unless induced with sufficient stimulation, indicating that these cells are not key 
regulators of Aβ/plaque levels in vivo in the presence of extensive A pathology. Thus, 
further experimentation is needed to determine the contributions of microglia at different 
stages in the disease and identify the ways in which GWAS-identified myeloid genes 
influence the onset and progression of AD.  
 
D. Microglial elimination via administration of CSF1R inhibitors 
Microglial depletion approaches 
 While various methods of microglial ablation are available, the technical requirements 
necessary to achieve sustained microglial elimination limit the utility of most depletion 
paradigms. For example, the CX3CR1creER x DTRff mouse model relies on 
administration of diphtheria toxin, which not only induces a cytokine storm, but also 
limits microglial elimination to 5 days120. The CD11b-HSVTK model requires 
intracerebroventricular infusion of ganciclovir in order to deplete appreciable numbers of 
microglia, which in turn induces BBB damage and myelotoxicity, resulting in increased 
mortality following 4 weeks of ganciclovir treatment104. Clodronate liposome 
administration is also reported to deplete microglia, however, this effect is short-lived 
and requires intrahippocampal infusion, as clodronate liposomes are incapable of 
crossing the BBB121. Thus, this highlights the need for more precise and targeted 
approaches to deplete microglia. 
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Colony-stimulating factor 1 receptor (CSF1R)  
CSF1R is expressed on all myeloid-derived cells and binding by one of the two CSF1R 
ligands (Colony-stimulating factor 1 (CSF-1) or interleukin 34 (IL-34)) leads to auto-
phosphorylation of the tyrosine kinase receptor. Following ligand binding, downstream 
signal transduction pathways are activated allowing for the regulation of myeloid cell 
differentiation, proliferation, migration, and survival122-125. Even though low expression 
of Csf1r has been reported in some neurons in the hippocampus126, CSF1R expression 
is predominantly restricted to microglia in the CNS. Genetic evidence for the 
consequences of CSF1R activation in vivo indicates that CSF1R primarily plays a 
homeostatic role in regulating the viability and proliferation of microglia127,128.  In mice, 
knockout of both CSF1R alleles is embryonically lethal and the brains of these mice lack 
microglia, indicating that signaling through this receptor is necessary for microglial and 
animal survival during developmental processes123,124. Moreover, genetic deletion of 
either of its ligands, CSF1129 or IL-34125, reduces microglial numbers without animal 
mortality, suggesting that compensatory actions by the remaining ligand of the CSF1R 
allows these mice to survive, as opposed to total knockout of the CSF1R. In humans, 
dominant loss-of-function mutations in CSF1R cause adult-onset leukoencephaopathy 
with axonal spheroids and pigmented glia (ALSP)130,131. The clinical manifestation of 
ALSP includes progressive white matter loss, memory decline, and motor impairments. 
Due to the specificity of CSF1R expression in microglia in the CNS, this demonstrates 
that perturbations in microglial function via altered CSF1R signaling alone can induce 
neurodegenerative phenotypes. Thus, techniques that manipulate CSF1R signaling 
may present a novel route to investigate and modulate microglial biology/numbers.  
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Microglia in the adult brain are dependent on CSF1R signaling for their survival 
Given the role of CSF1R in regulating microglial numbers, pharmacological inhibitors of 
this receptor were developed as an approach to investigate microglial dynamics. 
PLX3397 and PLX5622 are two CSF1R inhibitors initially developed as cancer 
therapeutics (Fig. 2), with PLX3397 in phase III clinical trials for Pigmented Villonodular 
Synovitus (PVNS). PLX5622 was designed using a structure-guided drug design 
strategy based on the existing CSF1R/KIT/FLT3 inhibitor PLX339735,132, combined with 
in vivo screening for optimal pharmacokinetics (PK) and brain penetrance. Two key 
structural differences between PLX5622 and PLX3397 contribute to the improved 
selectivity to CSF1R based on crystallographic analysis. In vivo, PLX5622 
demonstrated desirable PK properties in mice, rats, dogs, and monkeys, with a brain 
penetrance of ~20% (compared to ~5% for PLX3397)133. 
 
Figure 2 Chemical structures of CSF1R inhibitors PLX3397 and PLX5622. A, Chemical structure of 
selective CSF1R inhibitor PLX5622. PLX5622 is structurally similar to CSF1R/KIT/FLT3 inhibitor 
PLX3397 with modifications concentrated on the two pyridine moieties. B, X-ray crystal structure of the 
CSF1R-PLX5622 complex. The CSF1R selectivity is largely determined by the interaction between 
PLX5622 and Gly795 (represented as a sphere), which is a bulkier residue (cysteine) in KIT and FLT3. 
The substitutions on the tail pyridine ring also contribute to the selectivity. This group displaces the 
juxatemembrane (JM) region (absent in the structure) from the allosteric site. In contrast, PLX3397 binds 
CSF1R in the presence of the JM region. 
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Figure 3 CSF1R Inhibition Eliminates Microglia from the Healthy, Adult Mouse Brain 2-month-old 
wild-type mice (C57BL6/J; n=4-5/group) were treated with control diet or PLX3397 (290 mg/kg) for 21 
days. A, Representative coronal sections of the brain from a control-treated mouse (left) and PLX3397-
treated mouse (right). Microglial were immunolabeled with IBA1 and tissue was subsequently analyzed 
with Imaris Software to generate images with a white dot overlaying each IBA1
 
cell body.  
Previously, our lab demonstrated that microglia rely on CSF1R signaling for their 
survival in the healthy murine adult brain133. We found that oral administration of 
PLX3397 eliminates >90% of microglia within 7 days, and up to 99% by 21 days (Fig. 
3)133. As microglia are heavily implicated in shaping the synaptic landscape of the brain, 
we assessed behavior and cognition and found no abnormalities, indicating that 
microglia are not necessary for these domains in adulthood133. Biochemical and 
immunohistochemical approaches have shown no effects on other cell types in the brain 
(i.e., neurons, astrocytes, and oligodendrocytes) with CSF1R inhibition133, nor any 
significant effects on peripheral myeloid cells, highlighting the specificity of microglial 
elimination via pharmacological inhibition of the CSF1R. Another attractive feature of 
our approach is that microglial elimination is completely reversible. We demonstrate that 
20 
 
 
  
withdrawal of inhibitor stimulates rapid repopulation of the microglial compartment with 
new cells that are capable of fully reconstituting the brain with new microglia within 14 
Figure 4 Treatment with the CSF1R inhibitor PLX3397 
eliminates microglia in Rosa26-YFP mice. Two-month-old 
mice were treated with PLX3397 (600 mg/kg) for 7 days to 
eliminate microglia. A,  Schematic of the breeding strategy to 
yield offspring with YFP expressing microglia. B, 
Immunolabelling for microglia (IBA1 in red) and expression of 
YFP in CSF1R+-derived cells (YFP in green). C, 
Quantification of the number of YFP+ and IBA1+ cells is 
reduced in the cortex by 88% ( P < 0.0001) and 99% ( P < 
0.0001), respectively, with PLX3397 treatment. Statistical 
significance is denoted by * P <0.05. Error bars indicate SEM 
(n = 4/group). 
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days133. Importantly, multiple groups have utilized and verified PLX3397, as well as the 
CSF1R-specific inhibitor PLX5622, as an effective tool for studying and eliminating 
microglia134-138, without inducing adverse effects on cognitive function in healthy, adult 
mice35,139. To address the possibility that CSF1R inhibitor treatment induces the loss of 
the microglial signature without cell elimination, we obtained CSF1R-iCRE [FVB-
Tg(Csf1r-icre)1Jwp/J] and Rosa26 YFP(B6.129X1-Gt(ROSA)26Sor tm1(EYFP)Cos /J) 
reporter mice from The Jackson Laboratory. Crossing these mice yielded CSF1R-
iCRE/Rosa26YFP progeny that express yellow fluorescent protein (YFP) in all cells that 
either transiently or constitutively express CSF1R, which in the brain predominantly 
labels microglia (see schematic in Fig. 4A). Two-month-old mice were treated for 7 days 
with PLX3397 (600 mg/kg in chow) to eliminate microglia (Fig. 4B). We found that ~90% 
of YFP cells were depleted with 7 days of treatment (Fig. 4C), indicating that CSF1R 
inhibitor treatment results in the elimination of microglia, rather than a downregulation of 
microglia-associated genes. Thus, our lab has demonstrated with reproducibility that 
CSF1R inhibitor administration is an effective technique to ablate the microglial 
compartment. 
Prior to the start of my dissertation, our lab had utilized CSF1R inhibitors to eliminate 
microglia in healthy133 and diseased murine brains, using a model of inducible 
hippocampal neuronal lesion35,36 and the 3xTg-AD mouse model35,133,139. Given the 
increasing interest in microglia in AD pathogenesis, for my dissertation I sought to 
determine the precise roles these cells play over the course of disease progression 
using CSF1R inhibitor-induced microglial ablation. My findings are described in the 
following chapters of this dissertation.  
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CHAPTER ONE 
ESTABLISHING THE ROLES OF CHRONICALLY ACITVATED MICROGLIA IN AGED 
ALZHEIMER’S DISEASE MICE 
INTRODUCTION  
Alzheimer's disease (AD) is a progressive, neurodegenerative disease classically 
characterized by the presence of amyloid plaques and neurofibrillary tangles. However, 
histological studies demonstrate that neuroinflammation is also a key feature of the 
Alzheimer's disease brain140-144, as well as being prominently observed in amyloid 
precursor protein (APP) overexpressing transgenic mouse models145. These studies 
show that activated microglia surround extracellular plaques146-148, likely in an attempt to 
clear the toxic deposits, and stain positively for inflammatory markers, including major 
histocompatibility complex (MHC) class II, cyclooxygenase (COX)-2, tumor necrosis 
factor (TNF)-, interleukin (IL)-1, and IL-16149. Inevitably, the sustained activation of 
microglia results in a chronic neuroinflammatory response and the increased production 
of pro-inflammatory cytokines, such as TNF- and IL-1150-152. Previous investigations 
indicate that this chronic neuroinflammation response is synapto- and neurotoxic153-155 
and exacerbates cognitive decline156. Indeed, mouse models of AD display striking 
dendritic spine loss that is spatially associated with these microglia-surrounded 
plaques157-159. In humans, studies have identified synaptic loss as a correlate of, and a 
major contributor to, cognitive decline160,161. Of relevance, recent genome-wide 
association studies (GWAS) have uncovered several risk-associated genes in the 
development of sporadic AD162. Most of these risk genes are either expressed by 
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microglia or associated with their reactivity, including CD2AP163, CD33164, BIN1165, 
CR1166, PICALM167, ABCA7168, TREM2169, and CLU170. Thus, genetic changes in 
microglia-associated genes correspond strongly with an increased risk of developing 
AD. For these reasons, we hypothesized that microglia play a critical role in the 
development and progression of AD by limiting A/plaque loads but contribute to 
synaptic and neuronal loss.  
We have previously shown that microglia in the adult brain are fully dependent on 
CSF1R signaling for their survival 133. Administration of CSF1R inhibitors that cross the 
blood brain barrier (BBB) lead to brain-wide elimination of ~80% of all microglia within 7 
days of treatment. Moreover, these microglia remain eliminated for the duration of 
treatment, even for weeks or months. Since microglia are the only cell type to express 
CSF1R in the adult brain parenchyma, the effects of this treatment are largely restricted 
to this cellular compartment. Of note, peripheral myeloid populations are also known to 
express CSF1R, but those explored thus far are not dramatically eliminated by the 
doses and compounds used in this study133,134,171-173, although their functions/response 
to disease may be altered due to inhibition.  
In this study, we have set out to show that microglia in the AD brain are also dependent 
on CSF1R signaling and to explore the effects of chronic microglial elimination on AD 
pathologies and memory in 5xfAD mice. The 5xfAD mice represent an aggressive 
model of amyloid pathologies, with A plaques first depositing from 2 months of age174. 
Notably, 5xfAD mice exhibit marked synaptic and neuronal loss as pathology develops, 
with neuronal loss seen in the subiculum from 10 months of age175-178, allowing for 
investigations into how the pathology drives damage to neurons and neuronal 
24 
 
structures. Through the elimination of microglia in advanced pathology 5xfAD mice, we 
show recovery of contextual memory, a reversal of dendritic spine loss and prevention 
of neuronal loss, yet no changes on A levels or plaque loads, highlighting the roles that 
microglia may play in the AD brain.  
 
MATERIALS AND METHODS 
Compounds: PLX3397 was provided by Plexxikon Inc. and formulated in AIN-76A 
standard chow by Research Diets Inc. at 290 mg/kg or 600 mg/kg, as previously 
described133. PLX5622 was provided by Plexxikon Inc. and formulated in AIN-76A 
standard chow by Research Diets Inc. at 1200 mg/kg. 
 
Animal treatments: All rodent experiments were performed in accordance with animal 
protocols approved by the Institutional Animal Care and Use Committee at the 
University of California, Irvine. The 5xfAD mouse model has been previously described 
in detail174. Using a 2 × 2 factorial design, forty male and female 10-month-old wild-type 
(C57BL/6 background) or 5xfAD mice were treated with either PLX3397 for 28 days to 
eliminate microglia or control chow, creating four treatment groups (n = 10/group): 
Control (six males and four females), PLX3397 (six males and four females), 5xfAD 
(four males and six females), and 5xfAD + PLX3397 (four males and six females). At 
this age, 5xfAD mice display extensive pathology, synaptic loss, and neuronal 
loss174,175. After 28 days of treatment, behavioural testing commenced while animals 
remained on their respective diets. A second cohort of 14-month-old 5xfAD mice (n 
= 4/group; 5xfAD = four males, and 5xfAD + PLX5622 = three males and one female) 
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was treated with either PLX5622 for 28 days to deplete microglia or control chow (5xfAD 
versus 5xfAD + PLX5622). A third cohort of 1.5-month-old 5xfAD mice (n = 4/group; two 
males and two females) was treated with PLX3397 or control for 28 days (5xfAD versus 
5xfAD + PLX3397). Following behavioural testing in the 10-month-old cohort, and 
following inhibitor treatment in the 14-month-old and 1.5-month-old cohorts, mice were 
euthanized via CO 2 inhalation and transcardially perfused with phosphate-buffered 
saline. For both studies, brains were removed and hemispheres separated along the 
midline. Brain halves were either flash frozen for subsequent biochemical analysis, 
drop-fixed in 4% paraformaldehyde (Thermo Fisher Scientific) for subsequent 
immunohistochemical analysis, or placed in Golgi impregnation solution for subsequent 
dendritic spine analysis. Fixed half brains were sliced at 40 µm using a Leica SM2000 R 
freezing microtome. The flash-frozen hemispheres were ground with a mortar and 
pestle to yield a fine powder. One-half of the powder was homogenized in Tissue 
Protein Extraction Reagent, T-PER (Life Technologies) with protease (Roche) and 
phosphatase inhibitors (Sigma-Aldrich). The second half was processed with an RNA 
Plus Universal Mini Kit (Qiagen) for RNA analysis. 
 
Behavioural testing: Behaviour was analysed 28 days after the administration of 
PLX3397 treatment to eliminate microglia. Methods for testing mice on contextual fear 
conditioning were based on previous literature133,179. To assess contextual memory, 
freezing behaviour, defined as the total lack of body movement except for respiration, 
was scored live and video-recorded. Behaviour was scored using 1-0 sampling every 10 
s, with a 1 denoting positive freezing behaviour and 0 indicating the absence of freezing 
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behaviour. For the training trial, mice were placed in a fear-conditioning chamber 
(Gemini, San Diego Instruments; 24.1-cm length × 20.3-cm width × 20.3-cm height) and 
allowed to explore for 2 min before receiving one foot shock (3 s, 0.2 mA). Animals were 
returned to their home cage 30 s after the shock. Testing was conducted 24 h later, in 
which the animals were placed in the chamber and allowed to explore for 5 min. 
 
Confocal microscopy: Immunofluorescent labelling was performed following a 
standard indirect technique as previously described180. Primary antibodies and dilutions 
used are as follows: anti-ionized calcium-binding adapter molecule 1 (IBA1; 1:1000; 
Wako), anti-amyloid-β 1–16 (6E10; 1:1000; Covance), anti-s100β (1:200; Abcam), anti-
aldehyde dehydrogenase family 1 member L1 (Aldh1L1; 1:50; UC Davis), and anti-glial 
fibrillary protein (GFAP; 1:1000; Abcam). Thioflavin-S (Sigma-Aldrich) staining was 
carried out as previously described181. Total microglia and plaque counts were obtained 
by imaging comparable sections of tissue from each animal at the 10× objective, 
followed by automated analyses using Bitplane Imaris 7.5 spots or surfaces modules, 
respectively. To determine the number of plaque-associated microglia, equal perimeters 
were drawn around each plaque using ImageJ software (NIH), and cells were manually 
counted. 
 
Immunoblotting: Immunoblotting was performed as previously described 133. 
Antibodies and dilutions used in this study include: 6E10 (as described above), CT20 
(1:1000; Calbiochem) for C99 and C83, and β-actin (1:10,000; Sigma-Aldrich). 
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Quantitative densitometric analyses were performed on digitized images of immunoblots 
with ImageJ software. 
 
Amyloid-β enzyme-linked immunosorbent assay: Isolated protein samples were 
transferred to a blocked MSD Human/Rodent (4G8) amyloid-β triplex ELISA plate 
(amyloid-β1–38 , amyloid-β1–40 , amyloid-β1–42 ) and incubated for 2 h at room 
temperature with an orbital shaker. The plate was then washed and measurements 
obtained using a SECTOR Imager 2400, according to the manufacturer’s instructions 
(Meso Scale Discovery). 
 
NanoString RNA analysis: One hundred and eighty inflammation-, Alzheimer's 
disease-, plasticity-, and ageing-related genes were selected for analysis and probes 
were designed and synthesized by NanoString nCounter™ technologies (NanoString) 
against mouse genes. Total mRNA was extracted using an RNA Plus Universal Mini Kit 
(Qiagen) and was hybridized and multiplexed with NanoString probes, according to the 
manufacturer’s instructions. Counts for target genes were normalized to house-keeping 
genes (Eef1g, G6pdx, Hprt, Polr1b, Polr2a, Ppia, Rpl19, Sdha, and Tbp) to account for 
variability in the RNA content. Background signal was calculated as a mean value of the 
negative hybridization control probes. Normalized counts were log-transformed for 
downstream statistical analysis. 
 
Golgi staining and spine quantification: Half brains were sliced coronally with a 
vibratome at 100 µm, mounted on gelatin-coated slides, and subsequently stained using 
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a SuperGolgi Kit, per the manufacturer’s instructions (Bienno Tech). Five non-primary 
apical dendrites in the CA1 per animal (n = 3/group) were traced using a 100× oil-
immersion objective and Neurolucida software for dendritic spine analysis (MBF 
Bioscience). Spines were classified based on previous literature using head-to-neck 
ratios and quantified according to the following categories: total, mushroom, stubby, and 
thin spines182. 
 
Cresyl violet staining and neuron quantification: Cresyl violet staining was 
performed on fixed tissue and neurons in the subiculum were counted in a double-blind 
unbiased stereological fashion, as previously described183. All unbiased stereological 
assessments were performed using Stereo Investigator (MBF Bioscience) and 
Neurolucida softwares. The stereological quantification of neurons in the subiculum was 
performed on every sixth section (40 µm coronal sections between −2.48 mm and −3.28 
mm posterior to bregma) of one brain hemisphere (n = 4/group). A counting frame of 50 
× 50 µm in a sampling grid of 100 × 100 µm was used, with a guard zone height of 3 µm 
for the top and bottom. The subiculum was defined using a 5× objective and the Cresyl 
violet stained cells were counted using a 100× oil-immersion objective. Neuronal nuclei 
were randomly sampled from the defined subiculum using the optical dissector probes. 
 
Statistics: Behavioural, biochemical, and immunohistological data were analysed using 
either unpaired Student’s t -test (Control versus wild-type or 5xfAD versus 5xfAD + 
PLX3397/PLX5622) in Microsoft Excel or as a two-way ANOVA (Diet: Control versus 
PLX3397 and Genotype: wild-type versus 5xfAD) using the MIXED procedure of the 
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Statistical Analysis Systems software (SAS Institute Inc.), a general linear model that 
accounts for both fixed and random variables, as previously described 184. Post 
hoc paired contrasts were used to examine biologically relevant interactions from the 
two-way ANOVA regardless of statistical significance of the interaction. Symbols denote 
significant differences between groups (P < 0.05): *Control versus PLX3397; † Control 
versus 5xfAD; # PLX3397 versus 5xfAD + PLX3397; φ 5xfAD versus 5xfAD + PLX3397. 
Data are presented as raw means ± standard error of the mean (SEM). For all analyses, 
statistical significance was accepted at P < 0.05 (*) and trends at P < 0.10 (#). 
 
RESULTS 
CSF1R inhibition improves contextual memory deficits in 5xfAD mice following 
microglial elimination 
10-month-old 5xfAD mice were selected for this study as they show extensive amyloid 
pathology at this age, along with robust neuroinflammation and also synaptic loss, 
mimicking the human condition. Crucially, these mice begin to exhibit neuronal loss 
from 10 months of age. Following 28 days of PLX3397 or control chow treatment, 5xfAD 
and WT mice were tested in contextual fear conditioning to assess hippocampal 
memory (see experimental schematic; Fig. 1.1A, n=12/group). Analysis of behavioral 
performance revealed that 5xfAD mice spent significantly less time freezing compared 
to controls, but this effect trended toward recovery in 5xfAD mice administered 
PLX3397 to eliminate microglia (p=0.0813; Fig. 1.1B). Following behavioral testing, the 
brains of these mice were analyzed for Thioflavin-S (Thio-S) staining and IBA1 
immunolabeling to visualize dense core plaques and microglia, respectively (Fig. 1.1C 
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and D). 5xfAD mice had significantly elevated total numbers of IBA1+ cells, but these 
were reduced by ~80% in the hippocampus, cortex, and thalamus of PLX3397-treated 
animals (Fig. 1.1E), revealing the majority of these cells to be dependent on CSF1R 
signaling for their survival, particularly in the intra-plaque spaces. High power Z-stack 
images showed a high association of myeloid cells with dense core plaques in these 
mice (Fig. 1.1F). Importantly, PLX3397 treatment significantly reduced these plaque-
associated myeloid cells by ~50% (Fig. 1.1G). Quantification of the number of non-
plaque associated IBA1+ cells revealed a ~90% reduction in the treated 5xfAD mice 
(Fig. 1.1H), highlighting the preferential elimination of non-plaque associated IBA1+ 
cells.  
Moreover, immunolabeling tissue for the microglial-specific markers 4D4 (data 
unpublished) and P2RY12165 evidenced the plaque-associated myeloid cells in 5xfAD 
mice as microglia (Fig. 1.2A- C). We found a stark reduction in P2RY12 expression in 
PLX5622-treated mice compared to WT (Fig. 1.2C), confirming that CSF1R inhibitor 
treatment eliminates microglia in the healthy brain. Importantly, myeloid cells in 
PLX3397-treated 5xfAD mice also expressed the microglial-specific markers (Fig. 1.2B 
  
Figure 1.1 Chronically activated microglia in 5xfAD mice are dependent on CSF1R signaling for 
their survival: 10-month-old WT or 5xfAD mice were treated with control chow or PLX3397 for 28 
days to eliminate microglia. A, Experimental design. B, In contextual fear conditioning, 5xfAD mice 
spent significantly less time freezing compared to control (via two-way ANOVA, p=0.0196) and 5xfAD 
+ PLX3397 treated mice trended to an increased freezing time (via two-way ANOVA, p=0.0813). C, D, 
Immunolabeling for microglia (IBA1 in red) and staining for dense-core plaques (Thio-S in green). E, 
Microglia number is increased by ~40% in 5xfAD mice compared to control (via two-way ANOVA, 
p<0.0001). PLX3397 treatment eliminates ~80% of microglia in both WT and 5xfAD mice (via two-way 
ANOVA, p<0.001). F, Representative 63X IBA1 Thio-S immunofluorescent staining of the cortex. G, 
Quantification of plaque-associated microglia reveals the number of these cells was reduced by ~50% 
with PLX3397 treatment (two-tailed unpaired t-test, p<0.0001). H, The number of non-plaque 
associated microglia is reduced by ~90% with PLX3397 treatment in 5xfAD mice (two-tailed unpaired t-
test, p<0.0001). Statistical significance is denoted by *P<0.05 and statistical trends by #P<0.10. Error 
bars indicate SEM; (n=12/group for A and B, for n=7/group for C-G). 
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and D, as shown by white arrows), suggesting that a population of microglia are 
resistant to CSF1R inhibitor treatment. Combined, these findings indicate that microglia 
in 5xfAD mice may be involved in mediating contextual memory deficits, which can be 
partially attenuated by eliminating the microglial compartment. 
 
 
 
Figure 1.2 Surviving IBA1+ cells are of microglial identity. A, B, Representative cortical sections 
from 5xfAD groups stained for dense-core plaques (Thio-S in green) and immunolabeled for 
microglial cells (IBA1 in red, 4D4 in blue). C, D,  Cortical images of dense-core plaque staining (Thio-
S in green) and immunolabeling for microglia (P2RY12 in red), showing microglia surrounding Thio-S+ 
deposits (n=6-7/group).  
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Microglia do not modulate A pathology 
To determine if microglia mediate amyloid pathology, we examined the effects of 
eliminating microglia on A levels in the brain. Staining for dense-core plaques via Thio-  
S showed that microglial depletion did not significantly affect plaque numbers or 
average plaque size in any brain region analyzed (Fig. 1.3A-D). Plaques were 
categorized by size (i.e., <150m2, 150-1000 m2, or >1000 m2) in the thalamus, due 
to high plaque load observed in this region (refer to Fig. 1.3A-D), but no differences 
were found between control- and PLX3397-treated mice (Fig. 1.3E). We further 
analyzed both soluble and insoluble levels of A1-38, A1-40, and A1-42 by triplex ELISA. 
In WT mice, there was no effect of microglial elimination on levels of endogenous A 
species (Fig. 1.3F), while A1-38 was below detection limits. We also found no significant 
differences in A levels in either soluble or insoluble fractions in 5xfAD mice (Fig. 1.3G 
and H). Finally, we immunolabeled tissue with 6E10 antibody, to assess the effect of 
PLX3397 treatment on diffuse plaque load and quantified the size of plaques (Fig. 1.3I). 
In the cortex, we found no differences in diffuse plaque load or size with PLX3397 
treatment (Fig. 1.3J and K). Collectively, these data indicate that microglia do not play a 
substantial role in A production/clearance or plaque deposition/remodeling in 
pathological 5xfAD mice. 
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Elimination of microglia in young 5xfAD mice reveals no changes in A pathology 
Given the surprising result that elimination of microglia did not affect A load or levels in 
pathological 5xfAD mice, we sought to determine if microglia were protective at younger 
Figure 1.3 Elimination of microglia does not modulate A levels or plaque load. A, B, Representative 
hippocampal and thalamic 10X images of dense core plaques (Thio-S) in 5xfAD and 5xfAD mice 
treated with PLX3397. C, D, Quantification of number of Thio-S+ plaques and average area of the 
plaques in the hippocampus, cortex, and thalamus. E, Microglial elimination has no effect on plaques 
of any size. F, Levels of A1-40 and A1-42 were unchanged with microglial elimination in WT mice. 
Levels of A1-38 were below detection threshold. G, H, Levels of A species in detergent-soluble and 
formic acid-soluble (FA) fractions are not changed with microglial elimination. I, Representative 10X 
6E10 and IBA1 immunofluorescent images of the thalamus. J, K, Quantification of 6E10+ plaque size 
and numbers reveals no effect of microglial elimination. Error bars indicate SEM; (n=7/group). 
Figure 1.4 Microglial elimination in young 5xfAD mice does not affect A pathology: 1.5-month-
old 5xfAD mice were treated with PLX3397 or control chow for 28 days. A, Experimental design. B, 
C, Representative 10X immunofluorescent IBA1 and 6E10 images of the hippocampus and 
amygdala. D, Quantification of microglial cells shows a significant reduction in the 5xfAD + PLX3397 
group compared to the 5xfAD group in the hippocampus and amygdala (two-tailed unpaired t-test, 
p<0.0001). E, F, Levels of A species in detergent-soluble fractions are unchanged with the 
elimination of microglia. Levels of A1-38 in the detergent-soluble fraction were below detection 
threshold. Statistical significance is denoted by *P<0.05. Error bars indicate SEM; (n=4/group).  
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ages or in the absence of pathology. As 5xfAD mice develop plaques from ~2 months of   
age, we treated 1.5-month-old mice with PLX3397 for 28 days (Fig. 1.4A). 
Immunolabeling for IBA1 and 6E10 (Fig. 1.4B and C) revealed extensive intraneuronal 
6E10-reactivity in CA1 and amygdala neurons in both groups, but no extracellular 
plaques were observed. Microglial counts in these regions showed a ~95% decrease 
with PLX3397 treatment (Fig. 1.4D). To further analyze A, we used triplex ELISA to 
assess protein levels of A1-38, A1-40, and A1-42. We found no effect of microglial 
elimination on the amount of soluble (Fig. 1.4E) or insoluble (Fig. 1.4F) A protein. 
Together, these data indicate that microglia do not protect against A accumulation in 
the 5xfAD mice at a pre-plaque age. 
 
Elimination of microglia in aged 5xfAD mice with the specific CSF1R inhibitor 
PLX5622 
PLX5622 is a brain-penetrant inhibitor of CSF1R that quickly eliminates microglia, but 
does not inhibit c-kit134,139. In order to confirm the effects of PLX3397 and to rule out 
other off-target effects, we treated a second cohort of 14-month-old 5xfAD mice for 28 
days with 1200 mg/kg PLX5622 in chow. We again stained tissue for dense core 
plaques using Thio-S and immunolabeled microglia with IBA1 (Fig. 1.5A). Microglia 
were dramatically depleted with treatment, with most of the remaining cells being 
associated with dense core plaques, as with PLX3397 treatment (Figure 1.5B and E). 
Quantification revealed on average ~1 cell per plaque remaining (Fig. 1.5C), however, 
many plaques had 0 IBA1+ cells associated with them (Fig. 1.5D). Further analyses  
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revealed that all remaining IBA1+ cells had cell bodies containing A (Fig. 1.5K; shown 
by white arrows) – in contrast, most IBA1+ cells around plaques in untreated 5xfAD 
brains did not contain any A (Fig. 1.5J). Indeed, some of these IBA1+ cells in the 
treated mice were Thio-S positive (Fig. 1.5E panel). However, as with the PLX3397-
treated mice, we observed no change in the plaque area or total number (Fig. 1.5F and 
G), nor any significant changes in A protein levels (Fig. 1.5H and I), with this cohort of 
microglia-eliminated 5xfAD mice. 
 
 
AD-related gene transcription is altered in 5xfAD mice 
RNA was extracted from flash-frozen brain tissue from 10-month-old mice treated with 
PLX3397 to analyze transcript levels of 180 inflammation-, Alzheimer's disease-, age-
related genes, as part of a custom panel. Interestingly, transcript levels of Apoe, Cstc, 
and Cstd, which are implicated in lipid metabolism and protein degradation, 
respectively, were significantly increased in 5xfAD mice and attenuated with microglial 
elimination (Fig. 1.6A). No changes in APP, BACE1, or ADAM10 mRNA were found 
with either genotype or treatment. Similarly, AD-related signaling is largely unaffected 
by microglial elimination. In accordance with mRNA data, western blot analysis of 
steady-state levels of APP showed no differences with treatment (Fig. 1.6B and C). 
Figure 1.5 Elimination of microglia with PLX5622: 14-month-old 5xfAD mice were treated with 
PLX5622 or control chow for 28 days. A, B, and E, representative images showing dense-core 
plaques (Thio-S in green) and microglia (IBA1 in red) in the hippocampus and cortex. C, D, 
Quantification reveals ~65% decrease in plaque-associated microglia with PLX5622 treatment (two-
tailed unpaired t-test; p<0.0001) and a significant increase in specifically 0 to 1 IBA1+ cells associated 
with plaques in the PLX5622 group (two-tailed unpaired t-test; p<0.0001). F, G, Quantification of Thio-
S+ plaque areas and number of 6E10+ plaques shows no effect of microglial elimination. H, I, Levels 
of soluble and insoluble A species in 5xfAD mice show no significant changes with microglial 
elimination. J, K, 63X image of microglia (IBA1 in green), plaques (6E10 in red), and cell nuclei (DAPI 
in blue). Statistical significance is denoted by *P<0.05. Error bars indicate SEM (n=4/group).  
 
39 
 
Likewise, levels of the C-terminal fragments C99 and C83 showed no differences 
among groups (Fig. 1.6B and C). 
 
Figure 1.6 Modest changes in Alzheimer's disease-related genes with microglial elimination: 
transcript levels for Alzheimer's disease-related genes were analyzed using NanoString nCounter 
platform and immunoblots were performed to assess components of APP processing. A, Alzheimer's 
disease-related gene transcript levels in all four experimental groups. Symbols denote significant 
differences between groups (p<0.05): *Control vs. PLX3397; †Control vs. 5xfAD; #PLX3397 vs. 5xfAD 
+ PLX3397; 5xfAD vs. 5xfAD + PLX3397. B, C, Immunoblotting for full length APP, C99, and C83 
showed significantly increased levels of each protein in 5xfAD mice compared to Control (via two 
way ANOVA; p<0.0001) and in 5xfAD + PLX3397 mice compared to PLX3397 (via two way ANOVA; 
p<0.0001), but showed no effect of microglial elimination in 5xfAD mice. Statistical significance is 
denoted by *P<0.05. Error bars indicate SEM; (n=4/group). 
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Figure 1.7 Microglial elimination reduces neuroinflammatory signaling: RNA transcripts for 
inflammation-related genes were analyzed using NanoString nCounter platform. Symbols denote 
significant differences between groups (p<0.05): Symbols denote significant differences between 
groups (p<0.05): *Control vs. PLX3397; †Control vs. 5xfAD; #PLX3397 vs. 5xfAD + PLX3397; 5xfAD 
vs. 5xfAD + PLX3397. Error bars indicate SEM; (n=4/group). 
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Microglial elimination reduces inflammation-related gene transcripts  
Since microglia are the primary immune cells of the brain, we wanted to determine how 
inflammatory signaling as a whole was impacted by microglial elimination in 5xfAD 
mice. RNA levels of many inflammation-related genes were significantly increased in 
5xfAD mice compared to WT including complement (C1qa, C4a, and C3), chemokines 
(Ccl12, Ccl3, and Ccl5), and astrocytic genes (GFAP and S100). Crucially, the majority 
of increases are attenuated with microglial elimination in the 5xfAD mice (Fig. 1.7).  
 
Astrocyte numbers are largely unaffected with microglial elimination 
As reactive gliosis is an important feature of Alzheimer’s disease, we wanted to discern 
if microglial elimination impacts astrocyte numbers or responses. We immunolabeled 
tissue for reactive astrocytes using GFAP (green) and S100 (blue) with 6E10 (red) for 
plaques in the cortex and hippocampus (Fig. 1.8A, B, and D). GFAP expression is 
restricted to the hippocampal area in WT mice but is expressed in astrocytes around 
plaques in the cortex of 5xfAD mice, signifying reactive astrocytes. Accordingly, the 
number of GFAP+ astrocytes was also increased in the hippocampal area, whilst 
S100+ astrocytes were also increased in both brain regions examined (Fig. 1.8C). 
Notably, the number of GFAP+ cells was reduced in the cortex of 5xfAD mice treated 
with PLX3397, while treatment did not affect GFAP+ cells in the hippocampus, or 
S100+ cells in either brain region. We also probed for Aldh1L1+ astrocytes – another 
marker of astrocyte reactivity. No Aldh1L1+ cells were detected outside blood vessels in 
WT mice but were apparent in 5xfAD animals where they were also GFAP+ (Fig. 1.8E- 
G). Quantification of Aldh1L1+ astrocytes in hippocampus and cortex of 5xfAD mice 
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Figure 1.8 Astrocyte numbers are not affected by microglial elimination. A, B, 20X images of 
immunolabeling of astrocytes with GFAP (green) and S100 (blue) and plaques with 6E10 (red) in the 
cortex and hippocampus. C, Quantification revealed significant increases in GFAP+ and S100b+ cells 
in the 5xfAD mice compared to Control (via two-way ANOVA, p<0.001) and in 5xfAD + PLX3397 mice 
compared to PLX3397-treated mice (via two-way ANOVA, p<0.001). D, Representative 63X images 
of astrocytes and plaques in the cortex. E, F, 20X images of immunolabeling of astrocytes with GFAP 
(red) and Aldh1L1 (blue) with Thio-S staining plaques (green) in the cortex and hippocampus. G, 
Representative 63X images of astrocytes and plaques in the cortex. H, Quantification of Aldh1L1+ 
cells showed no changes in expression with microglial elimination. Statistical significance is denoted 
by *P<0.05. Error bars indicates SEM; (n=7/group). 
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showed no changes in expression with microglial elimination (Fig. 1.8H). 
 
Microglial elimination restores dendritic spine number in 5xfAD mice 
As activated microglia are thought to mediate synaptic stripping23,31, we sought to 
determine whether microglial elimination could affect dendritic spine number in 5xfAD 
mice. To that end, we stained tissue using the Golgi method (Fig. 1.9A) and counted 
and classified dendritic spines on non-primary apical dendrites in the CA1 region of the 
hippocampus (Fig. 1.9B and C). Total spine density was significantly decreased in 
5xfAD mice compared to WT and a recovery of this effect was observed following 
microglial elimination (Fig. 1.9D). Specifically, mushroom spines were significantly 
decreased in the 5xfAD mice compared to controls, but the elimination of microglia 
significantly increased mushroom spines in 5xfAD mice. Elimination also shows a trend 
toward recovery of thin spines in these mice (Fig. 1.9D). Together, these data confirm 
previous findings of significant spine loss in the 5xfAD mouse model, and indicate that 
microglia modulate this process, as the elimination of these cells allows for the 
regeneration of previously lost dendritic spines.  
 
 
Elimination of microglia prevents neuronal loss in 5xfAD mice 
An important and distinct feature of the 5xfAD mouse model is that these mice display 
overt neuronal loss in the subiculum at later stages176. As we had eliminated microglia 
over this crucial period, we stained brain tissue with cresyl violet to visualize cell nuclei 
and stereologically quantified the number of neurons in the subiculum (Fig. 1.9E).   
Quantification of neuronal populations revealed a significant decrease in neuronal 
number in the 5xfAD mice in the microglia-intact animals, whereas microglial elimination  
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Figure 1.9 Microglia modulate dendritic spine number in the CA1 and prevent neuronal loss in 
the subiculum of 5xfAD mice. A, Representative 2.5X image of Golgi staining in hippocampus and 
cortex. B, Representative 20X image of CA1 neurons and dendritic branches. C, Representative 
100X images of CA1 dendritic branches showing spines. D, The number of total (two-way ANOVA; 
p=0.0337) and mushroom (via two-way ANOVA; p=0.0091) dendritic spines is significantly decreased 
in 5xfAD mice, compared to control. 5xfAD + PLX3397 mice show significantly increased mushroom 
spine density (via two-way ANOVA; p=0.0416) and a trend for recovery of total spine loss (via two-
way ANOVA; p=0.0561), as well as a trend for increased thin spine density compared to 5xfAD (via 
two-way ANOVA; p=0.066). E, Representative 2.5X images of cresyl violet staining with the 
subiculum outlined in yellow. F, Stereological quantification of the number of neurons in the 5xfAD 
group showed a significant decrease in cell number compared to control (two-way ANOVA; p= 
0.0181). The neuronal loss in the 5xfAD group is prevented with microglial elimination in the 5xfAD + 
PLX3397 group (two-way ANOVA; p=0.0458). Statistical significance is denoted by *P<0.05 and 
statistical trends by #P<0.10. Error bars indicate SEM; (n=3-4/group).  
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in 5xfAD mice prevented this neuronal loss (Fig. 1.9F). These data corroborate previous 
reports of neuronal loss in the 5xfAD model in the subiculum at this age and indicate 
that microglia are actively contributing to neuronal loss in these mice. 
 
DISCUSSION 
 
The importance of microglia in Alzheimer's disease has been highlighted by GWAS, 
which have identified a number of single nucleotide polymorphisms (SNPs) associated 
with risk for the development of Alzheimer's disease that are associated with microglia 
function, including TREM2169, CD33185, BIN1186,187, and CR1188. Thus, understanding 
the various roles that microglia play in the healthy and Alzheimer’s disease brain are 
crucial in order to determine how these polymorphisms affect microglial function.  
We have previously shown that microglial elimination can be achieved in the healthy 
adult mouse brain by treatment with small-molecule inhibitors of the CSF1R133,139, with 
many groups confirming our findings134-137. We also found that chronically activated 
microglia following extensive neuronal injury can be eliminated with the same approach. 
Our studies also revealed that microglial elimination following neuronal insult improved 
functional outcomes, whereas elimination of microglia during the lesion exacerbated 
neuronal loss, revealing differential roles of microglia in injury response35. In this study, 
we sought to define the roles of microglia in mediating Alzheimer’s disease 
pathogenesis through the administration of CSF1R inhibitors at doses sufficient to 
eliminate microglia, rather than at lower doses that modulate microglial function without 
eliminating them. We first set out to determine if microglia in the brains of aged 5xfAD 
mice are still dependent on CSF1R signaling for their survival. Importantly, we show that 
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28 days of continuous treatment with either PLX3397 or PLX5622 leads to an ~80-90% 
reduction in microglia, respectively, throughout the CNS in adult 5xfAD mice.  
The elimination of microglia for 28 days from 5xfAD mice allows us to explore the role 
that these cells play in A and plaque homeostasis/pathogenesis. Traditionally, it has 
been thought that microglia respond to the presence of A plaques by helping clear 
them from the brain via phagocytosis of A-fibrils93. Reactive microglia have been 
shown to encircle plaques and A can be detected within their cytoplasm95,96,98. 
Furthermore, a recent study showed that microglia tightly surround plaques and prevent 
further growth117. However, results from a study of inducible microglial ablation found 
that eliminating microglia from the brains of APP overexpressing mice for 4 weeks does 
not affect plaque burden104. Our findings are in complete agreement with this, as we 
observed no changes in A levels, either soluble or insoluble following microglial 
elimination. Moreover, plaque load and average plaque size were also unaffected with 
CSF1R inhibitor treatment. Thus, microglia do not appear to affect brain A levels and 
are not a source of significant A clearance from the CNS, even in young, pre-
pathological mice. Notably, we found a subset of CSF1R-inhibitor resistant IBA1+ cells 
following treatment and further analysis revealed that many of these cells associated 
with dense core plaques and contained A within their cell bodies. The presence of 
these CSF1R-inhibitor resistant cells demonstrates heterogeneity of IBA1+ cells around 
plaques – even cells surrounding the same plaque may have different origins and 
functions. For example, recent studies that have crossed TREM2 knockout mice to APP 
mice, including the 5xfAD model, have demonstrated a stark reduction in plaque-
associated IBA1+ cells with TREM2 deletion. One study suggested that the reduction in 
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these cells was due to a lack of infiltrating monocytes from the periphery44 – as 
monocytes are not eliminated with the doses of CSF1R inhibitors used in this 
study134,173 – this could also explain the subset of CSF1R-inhibitor resistant cells around 
plaques. Alternatively, TREM2 can act as a survival signal in place of CSF1R 
signaling43, and it could be that a subset of IBA1+ cells around plaques upregulate 
TREM2, allowing them to survive in the presence of CSF1R inhibitors.  
As a parallel to our own findings, in a mouse model of glioblastoma multiforme with 
CSF1R inhibitor treatment, researchers found reduced numbers of tumor-associated 
IBA1+ cells, but not a complete eradication of these cells189, providing further support of 
the existence of heterogeneous populations of IBA1+ cells in the brain. Regardless of 
the origin of the surviving IBA1+ cells, more than 30% of plaques in treated mice had no 
IBA1+ cells associated with them, and as we observed no effect on plaque number or 
size, these findings suggest that remaining IBA1+ cells are not significantly contributing 
to the regulation or maintenance of A pathologies. Further evidence that microglia in 
the diseased brain are not protective against plaque development and growth has also 
come from studies with inducible APP transgenic mice, in which switching off the APP 
transgene after plaque formation does not lead to the breakdown of plaques by the 
brain115. Additionally, recent studies have shown that microglia around plaques are in a 
non-productive state due to overproduction of IL-10105, and that deletion of IL-10 
restimulates microglia to phagocytose and clear plaques190. Similarly, it has been shown 
that Prostaglandin E2 (PGE2) is overproduced in these conditions, and deletion of 
PGE2 stimulates the clearance of plaques106. Likewise, studies using Alzheimer's 
disease mice on a NOS2 null background (to mimic the human system) show that 
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microglia are suppressed around plaques and inhibitors of arginase can also restimulate 
these microglia to protect against Alzheimer's disease pathology107. Following the 
findings that microglia in the presence of Alzheimer's disease pathology appear to be 
suppressed, stimulation of microglia is known to induce plaque breakdown, with agents 
such as IL-1109, CSF1191, and lipopolysaccharide (LPS)108, as well as repeated 
scanning ultrasound treatments192. Collectively, these results are in congruence with our 
data and suggest that microglia in the Alzheimer's disease brain are not able to 
effectively clear A from the CNS or protect against plaque formation or growth. Thus, 
given their chronic reactivity, it is imperative to determine what effects microglia are 
exerting in the Alzheimer's disease brain. 
We found that elimination of microglia reduces brain-wide inflammatory signaling in 
5xfAD mice, as indicated by RNA analysis of several inflammation-related genes. We 
observed reductions in microglia reactivity-associated transcripts, including C1q, Tlr2, 
Tlr3, Tlr4, Tlr7, Ccl3, Nlrp3, and Pdcd1, as well as reductions in anti-
inflammatory/phagocytic markers, such as Tgfb1, Tgfbr1, Tgfbr2, Mrc1, and Itgb2. 
Additionally, our results show that elimination of microglia is beneficial for a 
hippocampal-dependent cognitive task. These findings are in line with many others that 
show modulating microglial function in Alzheimer's disease models can restore/improve 
memory193-196. Furthermore, others have shown that inflammatory factors are necessary 
for A-induced LTP deficits197. Altogether, this suggests that microglia contribute to the 
memory impairments seen in Alzheimer's disease transgenic mice. Microglia produce a 
plethora of modulatory substances, but also interact with the local brain environment, 
and it is likely a combination of these activities that contributes to impairments. For 
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example, in vivo, microglia have been shown to cause neuronal loss in Alzheimer's 
disease mice via signaling through CX3CR1, a chemokine receptor expressed by 
microglia involved in neuron-microglia communication198. Synaptic and neuronal loss is 
well documented in the 5xfAD model and is likely one mechanism contributing to deficits 
in contextual memory175-177. In our study, we find the total number of dendritic spines to 
be significantly decreased in 5xfAD mice compared to controls, and this is accounted for 
primarily by decreases in mushroom spines. Critically, the elimination of microglia 
reversed reductions in mushroom spines in 5xfAD mice, suggesting that the absence of 
microglia allows for the regeneration of lost spines seen in the Alzheimer's disease 
brain. Additionally, we found a significant reduction of neurons in the subiculum of 
5xfAD mice, which was prevented with the elimination of microglia, indicating an 
important and detrimental function of microglia in mediating neuronal loss in aged 5xfAD 
mice.  
Overall, our results show that microglia in the diseased brain are dependent on CSF1R 
signaling for their survival. Importantly, we find that chronic microglial elimination is not 
detrimental to animals, but rather, improves functional outcomes and disease-related 
synaptic aberrations, while preventing neuronal loss.  
  
50 
 
CHAPTER TWO 
ASCERTAINING MICROGLIAL FUNCTIONS IN ALZHEIMER’S DISEASE ONSET AND 
PROGRESSION 
INTRODUCTION  
Alzheimer’s disease (AD) is a progressive, age-related neurodegenerative disorder 
thought to be triggered by the appearance and build-up of amyloid-β (Aβ) plaques in the 
cortex199,200. These plaques subsequently spread throughout the forebrain and lead to a 
cascade of events, culminating in synaptic and neuronal loss that underlie the disease-
associated memory impairments. Genome-wide association studies have identified 
numerous genes that confer increased risk for developing the disease; however, the 
mechanisms underlying plaque formation remain unclear. Discerning commonalities in 
the function of these disease-associated genes may elucidate potential biological 
mechanisms involved in the production of plaques201. Several of the top identified risk-
conveying genes are highly enriched in myeloid cells (CR1, CD33, ABCA7, TREM2, 
MS4A, EPHA1, SPI1169,185,202), highlighting the link between myeloid biology and the 
risk for developing AD. Within the CNS, microglia perform homeostatic maintenance, 
immune-related, and phagocytic functions. Their reported capacity for Aβ phagocytosis 
and clearance203 led to the suggestion that age-related changes in microglial function 
reduce clearance of neuronally-derived Aβ from the brain204, thus allowing plaque 
formation, as modeled in ex-vivo systems94,205. Indeed, we and other groups report that 
following the initial period of plaque formation, microglia surround the plaques and 
subsequently mount a harmful and non-resolving inflammatory response. Despite this 
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response, however, Aβ clearance and plaque modulation/dynamics is 
unaffected115,132,206, yet the removal of the microglia at advanced stages of pathology 
protects against synaptic and neuronal loss132. Here, we set out to explore the 
contribution(s) of microglia to plaque formation in the initial stages of the disease, which 
requires prolonged depletion of microglia throughout the plaque-forming period. To that 
end, we designed, synthesized, and optimized a potent, specific, orally bioavailable, and 
brain-penetrant CSF1R inhibitor, PLX5622, to deplete microglia for >6 months in 5xfAD 
mice. With the elimination of microglia, we uncovered critical roles of these cells in 
plaque formation, compaction, and growth, mitigating neuritic dystrophy, and modulating 
hippocampal neuronal gene expression in response to A pathology. These results 
implicate microglia as critical and causative in the development and progression of 
multiple facets of AD. 
 
MATERIALS AND METHODS 
Compounds: PLX3397 (pexidartinib) was synthesized following the published 
procedure207. For long term dosing, the compounds were formulated in AIN-76A 
standard chow by Research Diets Inc. at 1200 ppm (PLX5622), 300 ppm (PLX5622), 
600 ppm (PLX3397), and 75 ppm (PLX3397).  
 
Animal Treatments: All rodent experiments were performed in accordance with animal 
protocols approved by the Institutional Animal Care and Use Committee at the 
University of California, Irvine. The 3xTg-AD208 and 5xfAD174 mouse models have been 
previously described in detail. At the end of treatments, mice were euthanized via CO2 
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inhalation and transcardially perfused with 1X phosphate buffered saline (PBS). For all 
studies, brains were removed, and hemispheres separated along the midline. Brain 
halves were either flash frozen for subsequent biochemical analysis or drop-fixed in 4% 
paraformaldehyde (PFA (Thermo Fisher Scientific, Waltham, MA)) for 
immunohistochemical analysis. Fixed half brains were sliced at 40 μm using a Leica 
SM2000R freezing microtome. The flash-frozen hemispheres were microdissected into 
cortical, hippocampal, and thalamic/striatal regions and then ground with a mortar and 
pestle to yield a fine powder. One-half of the powder from cortical and thalamic regions 
was homogenized in 500 or 250 μl Tissue Protein Extraction Reagent (TPER (Life 
Technologies, Grand Island, NY)), respectively, with protease (Roche, Indianapolis, IN) 
and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO) and centrifuged at 100,000 g 
for 1 hour at 4ºC to generate TPER-soluble fractions. For formic acid-fractions, pellets 
from TPER-soluble fractions were homogenized in 500 or 250 μl 70% Formic Acid and 
centrifuged at 100,000 g for 1 hour at 4ºC. Protein concentration in each fraction was 
determined via Bradford209 and Lowry assays (Bio-Rad, per manufacturer’s 
instructions). For RNA analyses, the second half of powder was processed with an RNA 
Plus Universal Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s 
instructions. 
 
Human Tissue: Human postmortem tissue from non-demented, non-demented high 
pathology, and Alzheimer’s disease subjects was obtained from the Alzheimer’s 
Disease Research Center, UC Irvine with consent from the UC Irvine Ethics Committee. 
Neuropathological examination included Braak and Braak staging for plaques and 
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tangles and diagnosis of neuropathological AD using National Institute on Aging-
Reagan criteria. 
 
Behavioral Testing: ANY-Maze software was employed to video-record and track 
animal behavior. The following behavioral paradigms were carried out as previously 
described132,133,174: 
Elevated plus maze (EPM):  Mice were placed in the center of an elevated plus maze 
(arms 6.2 x 66cm, with side walls 15 cm high on two closed arms, elevated 46 cm 
above the ground) for 5 min to assess anxiety.  
Morris water maze (MWM):  Mice were placed in a plastic circular pool filled with 
opaque tap water (water mixed with water-soluble white paint). A white plastic platform 
was submerged 0.5 cm below the surface of the water. Distinct two-dimensional visual 
cues were positioned around the perimeter of the pool. The pool was visually divided 
into four quadrants, and the hidden platform was placed in one of these quadrants (#2), 
where it remained throughout the acquisition trials. Visual cues were taped to the walls 
to allow mice to create a spatial map during acquisition of the task. At the beginning of 
each acquisition trial, mice were placed on the platform for 10 s and then subsequently 
placed in the pool (quadrants were pseudorandomized) to swim freely for 60 s or until 
the platform was located. After all mice completed four trials, they were returned to their 
home cages. Twenty-four hours after the last day of acquisition testing, the platform was 
removed and the mice were subjected to a 60 s probe trial to assess spatial memory for 
the platform location.  
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Flow Cytometry: Blood was drawn via cardiac puncture and incubated with 
ammonium-chloride-potassium lysing buffer for red blood cell lysis. Blood leukocytes 
were subsequently blocked with anti-mouse CD16/32 (BioLegend) and stained with 
fluorophore-conjugated antibodies A700 anti-mouse CD45, PE anti-mouse CD11b, 
APC-Cy7 anti-mouse CD11c, PE-Cy7 anti-mouse CD4, APC anti-mouse CD8 and FITC 
anti-mouse CD19 (BioLegend) as well as propidium iodide (PI; Invitrogen) for live/dead 
discrimination. Data were acquired on a BD FACSAria II and analyzed using the FlowJo 
software to assess peripheral cell counts. Cells were gated on CD45+PI- live singlets. 
 
Confocal Microscopy: Immunofluorescent labeling was performed on mouse and 
human brain sections following a standard indirect technique as previously described180. 
Mice were perfused with PBS prior to tissue fixation, followed by tissue sectioning to 
produce 40 µm thick floating sections. Human sections were obtained from 4% PFA 
drop-fixed regions of the middle frontal gyrus of the cortex and processed into 25 µm 
thick floating sections. Primary antibodies and dilutions used are as follows: anti-ionized 
calcium-binding adapter molecule 1 (IBA1; 1:1000; Wako, Osaka, Japan), anti-Aβ1-16 
(6E10; 1:1000; BioLegend, San Diego, CA), anti-A11 oligomers (A11; 1:100; Thermo-
Fisher Scientific), anti-amyloid fibrils OC (OC; 1:100; gifted from Charles Glabe, Irvine, 
CA), anti-Aβ1-42 (1:200, Abcam), anti-CD68 (1:500; Bio-Rad, Hercules, CA), anti-CD11b 
(1:50, Bio-Rad), anti-CD31 (1:200; BD Pharmingen, San Diego, CA), anti-−amyloid 
[pyroglutamate-3] (p3GluA; 1:500; Novus Biologicals, Littleton, CO), anti-lysosomal 
associated membrane protein 1 (LAMP1; 1:200; Santa Cruz Biotechnology, Dallas, TX), 
anti-amyloid precursor protein (APP), c-terminal (1:500; Sigma-Aldrich, St. Louis, 
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Missouri), anti-S100β (1:200; Abcam, Cambridge, MA), anti-Apolipoprotein E (ApoE; 
1:100; Abcam), and anti-glial fibrillary protein (GFAP; 1:1000; Abcam). Thioflavin-S 
(Thio-S; Sigma-Aldrich) staining was carried out as previously described181. Amylo-Glo 
(Biosensis, Thebarton, South Australia, AU) staining was performed according to the 
manufacturer’s instructions. Total microglia and plaque counts/volumes were obtained 
by imaging comparable sections of tissue from each animal at the 20X objective, at 
multiple z-planes, followed by automated analyses using Bitplane Imaris 7.5 spots or 
surfaces modules, respectively. Plaque circularity was evaluated using ImageJ 
software. Hemisphere stitches were imaged using StereoInvestigator Software on a 
Zeiss Imager.M2 Stereology Scope. Three-dimensional reconstruction of microglia and 
plaques was generated using the surfaces module of Bitplane Imaris 7.5.  
 
Immunoblotting: Immunoblotting was performed as previously described132,133. 
Antibodies and dilutions used include anti-6E10 (as described above), anti-APP C-
Terminal (1:1000; Calbiochem, San Diego, CA) for C99 and C83, anti-ADAM10 (1:1000; 
Abcam), anti--secretase 1 (BACE1; 1:1000; Abcam), anti-Presenilin-1 (PS1; 1:1000; 
Abcam), anti-Presenilin enhancer 2 (PEN2; 1:500; Abcam), anti-A11 (1:1000, Thermo-
Fisher Scientific), and anti--actin (1:10,000; Sigma-Aldrich). Quantitative densitometric 
analyses were performed on digitized images of immunoblots with ImageJ software. 
 
Aβ ELISA: Isolated protein samples were transferred to a blocked MSD Human (6E10) 
Aβ triplex ELISA plate (Aβ1-38, Aβ1-40, Aβ1-42) and incubated for two hours at room 
temperature with an orbital shaker. The plate was then washed and measurements 
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obtained using a SECTOR Imager 2400, per the manufacturer’s instructions (Meso 
Scale Discovery, Gaithersburg, MD). 
 
RNA Sequencing: Whole transcriptome RNA sequencing (RNA-Seq) libraries were 
produced from Wild-type (WT), PLX5622, 5xfAD, and 5xfAD + PLX5622 mice treated 
from 1.5 – 7 months of age, brains that were microdissected into Cortex, Hippocampus, 
and Thalamus (n=4/group for each of the 3 brain regions = 48 total samples). Briefly, 
100-600ng of RNA were depleted of ribosomal RNA, fragmented, reverse transcribed 
and ligated to indexed sequencing adapters using the KAPA RNA HyperPrep Kit with 
RiboErase.  Amplified libraries were combined into 4 pools of 12 libraries and 
sequenced on 4 lanes of a HiSeq4000 producing 50bp single-end reads.  This work 
used the Vincent J. Coates Genomics Sequencing Laboratory at UC Berkeley, 
supported by NIH S10 OD018174 Instrumentation Grant. 
Reads were mapped to the reference mouse genome (mm10) using STAR210 aligner 
and quantified with the featureCounts function of the Rsubread211 package in R212. After 
filtering out low-count genes, count distributions were scaled using the calcNormFactors 
function of the edgeR213 package. Transgene/human alignments were not filtered out 
from mouse reads.  Principal component analysis was performed using the plotMDS 
function of the limma214 package in R. Normalized counts were prepared and fitted to 
linear models using the voom and lmfit functions of limma respectively. Gene set testing 
was performed using the camera function of the limma package. 
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Statistics: Every reported n is the number of biologically independent replicates. No 
statistical methods were used to predetermine sample sizes; however, our sample sizes 
are similar to those reported in recently published similar studies132,215. Behavioral, 
biochemical, and immunohistological data were analyzed using either two-tailed 
independent-samples t-test (Control vs. Wild-type (WT) or 5xfAD vs. 5xfAD + 
PLX3397/PLX5622) in Microsoft Excel or as a one- (Diet: Control vs. 
PLX3397/PLX5622 vs. Repopulation) or two-way ANOVA (Diet: Control vs. 
PLX3397/PLX5622 and Genotype: WT vs. 5xfAD) using GraphPad Prism Version 6 (La 
Jolla, CA). Tukey’s post hoc tests were employed to examine biologically relevant 
interactions from the two-way ANOVA regardless of statistical significance of the 
interaction. For RNA analyses, moderated t-statistics and corresponding p-values (raw) 
were calculated for each of the relevant comparisons for each gene (5xfAD vs. WT in 
cortex, hippocampus, or thalamus, 5xfAD + PLX5622 vs. 5xfAD in cortex, hippocampus, 
or thalamus, and WT + PLX5622 vs. WT in cortex, hippocampus, or thalamus), as well 
as the comparisons between brain regions (cortex vs. hippocampus, cortex vs. 
thalamus, and hippocampus vs. thalamus for both WT and 5xfAD mice) using the 
eBayes function in limma.  Raw p-values were adjusted across all comparisons to 
account for multiple testing using the decideTests function (Benjamini-Hochberg 
method).  Genes with an adjusted p-value below 0.05 were considered differentially 
expressed. Data distribution was assumed to be normal, but this was not formally 
tested. Symbols denote significant differences between groups: *p<0.05, **p<0.01, and 
***p<0.001. Statistical trends are accepted at p<0.10 (#). Data are presented as raw 
means and standard error of the mean (SEM). 
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RESULTS 
Non-plaque associated microglia contain A aggregates in mouse models of AD 
and humans 
The aggregation of A is an initial step in the formation of plaques, requiring an acidic 
pH216 and micromolar concentrations of Aβ monomers217. The extracellular space does 
not meet these requisite conditions, suggesting that Aβ aggregation originates 
elsewhere. In contrast to the extracellular space, microglial lysosomes provide a 
suitable environment to facilitate A aggregation, potentially contributing to the onset of 
plaque pathology218. To investigate the potential for microglia-mediated plaque 
formation, we examined Aβ aggregates within microglia in transgenic mouse models of 
AD. In 15-month-old 3xTg-AD mice, a time point at which plaques are beginning to 
form, we stained tissue for Thio-S (aggregated Aβ), microglia, and lysosomes. While 
plaque-associated microglia show accumulation of aggregates within their lysosomes 
(Fig. 2.1A, B; as well established219), we also observed non-plaque-associated 
microglia, including ramified microglia, accumulating aggregates within lysosomal 
compartments (Fig. 2.1C, D), and microglia containing intracellular aggregates the size 
of small plaques (Fig. 2.1E, F). The absence of nearby plaques suggests that existing 
aggregated A was not the source of these intracellular deposits. Similarly, non-plaque-
associated microglia in 4- and 7-month old 5xfAD brains also showed accumulation of 
Thio-S+ material (Fig. 2.1G-J), as well as aged human postmortem brains, including 
non-demented, high pathology non-demented, and Alzheimer’s disease subjects (Fig. 
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2.1K-P). Thus, microglia in plaque-forming regions in mouse and human brains can 
accumulate aggregated Aβ intracellularly, and we hypothesize that this could be an 
initial and crucial step toward plaque formation. 
 
Extended elimination of microglia does not induce cognitive or peripheral 
circulating cell abnormalities   
Having designed and optimized PLX5622 for microglia depletion, we sought to explore 
the contributions of these cells in the initial stages of AD pathology. To that end, 5xfAD 
animals, which exhibit plaque pathology from 3 months of age, underwent treatment at 
1.5 months of age with PLX5622-formulated chow (1200 ppm) or control diet 
continuously for either 10 or 24 weeks. Four treatment groups were included: Wild-type, 
PLX5622, 5xfAD, and 5xfAD + PLX5622 (n=12/group; sex-balanced; Fig. 2.2A). Initial 
characterization focused on the 24-week treated animals. Terminal PK values revealed 
no differences between PLX5622-treated groups in either plasma or brain (Fig. 2.2B) 
and no significant differences were seen in circulating leukocyte subsets (Fig. 2.2D) with 
treatment.  
Figure 2.1: Plaque-distal microglia contain aggregated A.  A-C, E, 15-month-old 3xTg-AD mice 
were stained for dense core deposits with Thio-S (in green), and immunolabeled for microglia (IBA1 
in red) and macrophage lysosomes (CD68 in blue; A, C, and E) with zoomed image (B) of Thio-S+ 
material within microglia and within lysosomes, separately. D-F, Three-dimensional reconstruction of 
microglia (IBA1 in red), the microglial lysosome (CD68 in purple), and fibrillar Aβ (Thio-S in green), 
demonstrating the localization of Aβ to the microglial lysosome in non-plaque associated microglia. G-
J, 5xfAD animals stained for dense-core deposits (Thio-S in green) and immunolabeled for microglia 
(IBA1 in red; G and I), with zoomed images (H and J) demonstrating Thio-S+ aggregates in microglial 
cell bodies in 4- and 7-month-old 5xfAD mice. K, M, O, Representative images from human cortical 
sections of non-demented, high pathology non-demented, and AD subjects, respectively, stained for 
Aβ plaques (Amylo-Glo in green) and microglia (IBA1 in red). L, N, P, Three-dimensional 
reconstruction of microglia (IBA1 in red) and aggregated A (Amylo-Glo in green), showing plaque-
distal microglia containing A.  
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In the brain, 5xfAD mice displayed increased numbers of microglia/myeloid cells at both 
4 and 7 months of age compared to wild-type mice, with masses of enlarged, plaque-
associated cells seen throughout the brain (Fig. 2.2C). Oral PLX5622 treatment led to 
almost complete microglial elimination (97-100% reduction; Fig. 2.2C and quantified in 
E and F), even with 24 weeks of treatment, showing that PLX5622 allows for extended 
elimination of microglia. Given the unprecedented absence of microglia for ~6 months, 
or essentially the entire adult lives of the animals, we conducted a battery of behavioral 
and cognitive performance tests. The extended absence of microglia in wild-type mice 
Figure 2.2: Long-term elimination of microglia with PLX5622 treatment does not induce 
peripheral leukocyte or behavioral abnormalities. 1.5-month-old wild-type (WT) or 5xfAD mice 
were treated with control chow or PLX5622 for 10 or 24 weeks to eliminate microglia. A, Experimental 
design. B, Terminal PK of PLX5622 and 5xfAD + PLX5622 groups showed no differences in drug 
concentration in the plasma or brain. Two-tailed independent t-test. n = 5-6 for PLX5622, n = 8-11 for 
5xfAD + PLX5622. C, Representative hemisphere stitches of immunolabeling for microglia (IBA1 in 
green) 7-month-old cohort. D, Analysis of different subsets of leukocytes showed no significant 
alterations with PLX5622 treatment compared to WT (p=0.059 for CD11b and p=0.052 for CD19, all 
others NS). NS, not significant. Two-tailed independent t-test; n = 4-5 for Wild-type, n = 3-4 for 
PLX5622. E, Quantification of microglial number in 4-month old animals revealed an elevation in 
5xfAD mice compared to WT (p=0.001, NS, p<0.001) and reductions in microglial number in 
PLX5622 (p<0.001, p<0.001, p=0.044) and 5xfAD + PLX5622 groups (p<0.001, p<0.001, p<0.001). 
All analyses listed in respective order for retrosplenial (RS) cortex, somatosensory (SS) cortex, and 
thalamus. NS, not significant. Two-way ANOVA with Tukey’s post hoc test; n = 5 for Wild-type, n = 4 
for PLX5622, n = 8 for 5xfAD, n = 9 for 5xfAD + PLX5622. F, In 7-month-old animals, microglial 
number is increased in 5xfAD mice compared to WT (p=0.015, p=0.024, p<0.001). Lifelong CSF1R 
inhibitor treatment eliminates 99% and 97% of microglia in PLX5622 (p<0.001 for all regions) and 
5xfAD + PLX5622 mice (p<0.001 for all regions), respectively. All analyses listed in respective order 
for retrosplenial (RS) cortex, somatosensory (SS) cortex, and thalamus. Two-way ANOVA with 
Tukey’s post hoc test; n = 4-5 for Wild-type, n = 6 for PLX5622, n = 5-8 for 5xfAD, n = 6 for 5xfAD + 
PLX5622. G, 5xfAD + PLX5622 mice entered the open arm more (p=0.007) and the closed arm less 
(p<0.001) than PLX5622 mice. Additionally, 5xfAD animals entered the closed arm less than WT 
(p=0.050), which was further enhanced with PLX5622 treatment in 5xfAD mice (p=0.056). H, The 
5xfAD group spent more time in the open arm (p=0.016) and less time in the closed arm (p=0.046) 
compared to WT. This phenotype was exacerbated in the 5xfAD + PLX5622 group, as these mice 
spent more time in the open arm (p<0.001) and less time in the closed arm (p=0.020) than the 5xfAD 
group. Additionally, the 5xfAD + PLX5622 group spent more time in the open arms (p<0.001) and 
less time in the closed arms (p<0.001) than the PLX5622 group. I, Morris water maze (MWM) 
acquisition revealed no differences between groups for time to locate platform over training trials. J, 
In MWM probe test, platform entries trended to an increase in PLX5622 mice compared to 
5xfAD+PLX5622 animals (p=0.071). K, For time spent in platform zone in MWM probe test, time in 
platform zone trended to an increase in the PLX5622 group relative to wild-type (p=0.094) and 
5xfAD+PLX5622 mice (p=0.073). For all behavioral analyses: Two-way ANOVA with Tukey’s post 
hoc test; n = 8-12 for Wild-type, n = 8-12 for PLX5622, n = 9-12 for 5xfAD, n = 8-9 for 5xfAD + 
PLX5622. Statistical significance is denoted by *p<0.05, **p<0.01, and ***p<0.001. Statistical trends 
are denoted by #p<0.10. Error bars indicate SEM. 
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did not induce any measurable negative effects in tests of anxiety (Fig. 2.2G, H). 
Compared to wild-type animals, 5xfAD mice showed altered behaviors in the elevated 
plus maze, which were further exacerbated with microglial elimination (Fig. 2.2G, H). To 
assess hippocampal-dependent memory, mice underwent testing using Morris water 
maze (MWM). In acquisition trials, 5xfAD mice did not show impairments (Fig. 2.2I). 
Interestingly, in the probe portion of the MWM, PLX5622-treated wild-type mice tended 
to spend more time in the platform zone compared to wild-type mice (Fig. 2.2K), 
indicating that the long-term absence of microglia is not detrimental to murine cognitive 
function and may be beneficial, consistent with our prior findings35,133.    
 
 
The absence of microglia diminishes plaque formation and shifts A 
accumulation to the vasculature  
Having demonstrated robust microglial elimination prior to and throughout the period of 
plaque formation in 5xfAD mice, we next determined the consequences of microglial 
ablation on pathology. In wild-type mice, CSF1R inhibitor treatment for 10 weeks 
eliminated >99% of microglia in the cortex (Fig. 2.3A, C, and F), but a fraction of cells 
remained in the thalamus (Fig. 2.3I). Treatment of 5xfAD mice with PLX5622 again 
reduced >99% of microglia in the cortex (Fig. 2.3D, G), but as with wild-type mice, a 
fraction of cells remained in the thalamus (Fig. 2.3J). In the absence of microglia, we 
observed a stark lack of dense-core plaques within cortical regions (quantified in Fig. 
2.3L; retrosplenial (RS) and somatosensory (SS) cortices examined). Notably, a band of 
plaques were found in the RS cortex, but these were all associated with a few microglia 
that had survived treatment (Fig. 2.3D, D1). Plaques were also formed within the  
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thalamus but were again predominantly associated with the remaining microglia that 
had survived the treatment (Fig. 2.3J). Close examination of the Thioflavin-S (Thio-S) 
stained slices revealed deposits beginning to form within cortical blood vessels (Fig. 
2.3D, G – yellow arrows). These results suggest that microglia are critical regulators of 
plaque formation and that few surviving microglial cells are sufficient to facilitate some 
degree of plaque formation (i.e., as seen in the thalamus).  
Consistent with the 10-week treated 5xfAD mice, examination of pathology in the 24 
week treated mice revealed diminished Thio-S+ dense-core plaque numbers in the 
cortices of the 5xfAD mice devoid of microglia (Fig. 2.3E, H; quantified in M). In the 10-
week treated cohort, we noted the appearance of plaques in areas that exhibited small 
populations of surviving microglia (RS cortex and thalamus; Fig. 2.3D and J). With an 
additional 14 weeks of treatment (i.e., 24 weeks treated animals), microglia were 
Figure 2.3: Long-term elimination of microglia in 5xfAD mice reduces plaque number and 
volume and is accompanied by cerebral amyloid angiopathy (CAA) onset. All analyses listed in 
respective order for retrosplenial (RS) cortex, somatosensory (SS) cortex, and thalamus. A, 
Representative hemisphere stitches of dense-core deposits stained with Thioflavin-S (Thio-S) in 
green and microglia (IBA1 in red) B, Representative images of brain hemispheres stained for dense-
core plaques (Thio-S in green) with immunolabeling for blood vessels (CD31 in red) alongside Thio-S 
(B1), illustrating the appearance of cerebral amyloid angiopathy (CAA) throughout the cortex of 5xfAD 
mice devoid of microglia. C-D, F-G, I-J, Confocal images of sections from 10 week treated animals 
stained for dense-core plaques (Thio-S in green) and immunolabeled for microglia (IBA1 in blue). E, 
H, K, Images from 24 week treated animals stained for dense-core plaques (Thio-S in green) and 
immunolabeled for microglia (IBA1 in red) and diffuse plaques (6E10 in blue). L, 5xfAD mice treated 
with PLX5622 for 10 weeks exhibited reductions in Thio-S+ plaque number relative to untreated 5xfAD 
mice (p<0.001, p<0.001, p=0.001). Two-tailed independent t-test; n = 7 for 5xfAD, n = 8 for 5xfAD + 
PLX5622. M, Quantification of Thio-S+ plaque number in 7-month-old mice revealed a 40-70% 
decrease in 5xfAD + PLX5622 mice (p=0.001, p=0.004, p=0.041) compared to untreated 5xfAD mice. 
Two-tailed independent t-test; n = 7-8 for 5xfAD, n = 5-6 for 5xfAD + PLX5622. N, Plaque volume in 
7-month-old mice was reduced by 45%-75% in the RS cortex and thalamus (p=0.003, NS, p=0.007) 
of 5xfAD mice treated with the CSF1R inhibitor and was unchanged in the SS cortex. NS, not 
significant. Two-tailed independent t-test; n = 7-8 for 5xfAD, n = 5-6 for 5xfAD + PLX5622. O-P, 
Immunolabeling 7-month-old 5xfAD animals for 6E10 and pyroglutamate-3-modified A revealed 
reductions (p=0.002 and p=0.008, respectively) in cortical expression of these amyloid markers with 
PLX5622 treatment. Two-tailed independent t-test; n = 4-5 for 5xfAD, n = 4-5 for 5xfAD + PLX5622. 
Q-S, 7-month-old PLX5622-treated 5xfAD animals stained for dense core deposits (Thio-S in green) 
and immunolabeled for oligomeric A (A11), protofibrillar A (OC) and A1-42, respectively.  
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completely eliminated from the brain (Fig. 2.3E, H, and K), but Thio-S plaques persisted 
in these areas (i.e., the thalamus and RS cortex). Average plaque volumes were ~30-
40% smaller, across all brain regions (Fig. 2.3N), suggesting that microglia contribute to 
plaque growth in the 5xfAD brain. Thus, even with increased treatment duration to 7 
months of age, plaque formation is prevented in the absence of microglia. Notably, 
abundant Thio-S staining was discovered within large cortical blood vessels in the 
5xfAD mice devoid of microglia (i.e., Fig. 2.3E, H), indicative of cerebral amyloid 
angiopathy (CAA). Whole brain stitches of Thio-S staining show clear vascular 
pathology rather than cortical plaques in microglia-depleted 5xfAD mice (Fig. 2.3B). 
Colocalization of Thio-S with the endothelial cell marker CD31 confirms the 
accumulation of Aβ within blood vessels (Fig. 2.3B1). The appearance of CAA occurred 
only in 5xfAD mice in the absence of microglia, as CAA was not observed in untreated 
5xfAD mice or in treated wild-type mice. In addition to Thio-S, CAA and plaques stained 
for fibrils, via the conformation specific antibody OC220 (Fig. 2.3R) and Aβ42 (Fig. 2.3S), 
but were negative for oligomers via A11 antibody221 (Fig. 2.3Q). Staining for 
pyroglutamate-3 Aβ (data not shown), which forms the plaque cores222, revealed a 
sharp reduction in immunoreactivity in PLX5622-treated 5xfAD mice relative to 
untreated 5xfAD animals in the cortex (Fig. 2.3P), along with reductions in 6E10+ diffuse 
plaques (Fig. 2.3O). Of note, pyroglutamate-3 immunoreactivity was found in areas of 
treated 5xfAD mice that exhibited plaque pathology (i.e., thalamus; not shown).  
The absence of microglia did not significantly alter the levels of Aβ38, Aβ40, or Aβ42, in 
detergent-soluble or -insoluble cortical and thalamic homogenates in either the 4- or 7- 
month cohorts (Fig. 2.4A-H), in line with multiple studies showing that CSF1R inhibition 
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does not affect Aβ production/clearance132,139,215. Thus, the absence of microglia 
modulates the location of Aβ accumulation (i.e., parenchyma vs. vasculature) but does 
not alter the net amounts present. Investigations into oligomeric species of A (via A11 
immunoblotting) found no significant changes in protein levels with microglia elimination 
in 5xfAD mice (Fig. 2.4I, J). To confirm that APP processing was unchanged with 
microglia elimination in 5xfAD mice at the protein level, we immunoblotted cortical tissue 
for various components of the APP processing pathway including APP and its cleavage 
products, as well as proteins associated with - (ADAM10), - (BACE1), and - (PEN2 
and PS1) secretase activity. We found significant elevations in full-length (fl) APP and 
Carboxy-terminal fragments of APP (C99 and C83) in 5xfAD mice relative to wild-type 
(Fig. 2.4K, L), but observed no differences in protein levels with PLX5622 treatment in 
5xfAD animals. Additionally, gene expression analyses of AD-related genes were 
performed (Fig. 2.4M; methods described in greater detail for Figs. 2.8 and 2.9) and we 
found no overt changes with microglia depletion. Collectively, these data indicate that 
Figure 2.4: No detectable alterations in A levels or APP processing with microglia elimination 
in 5xfAD mice. A-H, A levels from cortical (A-B, E-F) or thalamic brain homogenates (C-D, G-H) 
from 5xfAD mice treated with vehicle or PLX5622 (1200 ppm in chow) from 1.5 months of age to 
either 4 (A-D), or 7 (E-H) months of age, for both the detergent-soluble and insoluble fractions. In the 
4-month-old mice, insoluble A1-38 and A1-40 were below detection threshold. In the 7-month-old 
mice, insoluble A levels were plotted on log(10) scale and insoluble A1-38 was below detection 
threshold. Two-tailed independent t-test. For 4-month-old cohort: n = 3-6 for 5xfAD, n = 4-6 for 5xfAD 
+ PLX5622. For 7-month-old cohort: n = 5-6 for 5xfAD, n = 5-6 for 5xfAD + PLX5622. I-J, Cortical 
homogenates of 7-month-old mice immunoprobed and quantified, respectively, for A11. Two-tailed 
independent t-test; n = 7 for 5xfAD, n = 8 for 5xfAD + PLX5622. K-L, Immunoblotting and 
quantification, respectively, for components of the amyloid-precursor protein (APP) processing 
pathway in cortical homogenates from 7-month-old animals. Full length APP and APP Carboxy-
terminal fragments C99 and C83 are increased in 5xfAD animals relative to Wild-type (p=0.009, 
p=0.031, p=0.033, respectively), but no significant alterations in protein levels were observed with 
microglia elimination in 5xfAD animals. Two-way ANOVA with Tukey’s post hoc test; n = 4 for Wild-
type, n = 4 for PLX5622, n = 4 for 5xfAD, n = 4 for 5xfAD + PLX5622. M, Left panel - heatmap of 
log(2) fold change of genes associated with Alzheimer’s disease, including APP/A production and 
metabolism shown for each of the 9 comparisons and the 6 comparisons between brain regions. 
Right panel – heatmap of the corresponding p-values for each of the comparisons. Log(2) fold 
change and p-values indicated by respective scale bar. n = 4 for all groups. Error bars indicate SEM. 
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microglia elimination via PLX5622 treatment does not induce alterations in APP 
processing or other AD-related genes that could account for the reduction in plaque 
pathology.   
 
Microglial plaque compaction ameliorates the extent of neuritic dystrophy in 
5xfAD mice 
Upon examining caudal brain regions, we found some IBA1+ cells present within the 
subiculum and associated white matter tracts in the otherwise microglia-devoid 5xfAD 
animals (mice treated through 1.5-7 months of age; Fig. 2.5A, B). While PLX5622 
treatment extensively reduced myeloid cell numbers in the subiculum (77% reduction; 
Fig. 2.5C), there was a tight spatial association between the surviving cells and Thio-S 
plaques (Fig. 2.5A1, B1), similar to that seen in the thalamus of the 10-week-treated 
5xfAD mice (Fig. 2.3J). In fact, plaques were predominantly observed in the immediate 
vicinity of surviving IBA1+ cells – within the subiculum and associated white matter tract 
– while the cortex contained only vascular Thio-S+ deposits, in stark contrast to 
untreated 5xfAD mice (Fig. 2.5A vs. B). Quantification of Thio-S+ subicular plaques 
revealed a 33% decrease in plaque number (Fig. 2.5D) with PLX5622 treatment in 
5xfAD mice. Importantly, these results highlight a clear relationship between 
microglia/myeloid cells, even when substantially reduced in number, and the 
appearance of plaques. This relationship/association provides further evidence for a 
role of microglia/myeloid cells in facilitating the formation of plaques, and again 
emphasizes that few cells are required for this process to occur.  
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Structural examination of the plaques that had formed in PLX5622-treated 5xfAD mice 
(treated through 1.5-7 months of age), presumably due to the presence of surviving 
microglia at the time of their formation, revealed morphological differences compared to 
plaques formed and maintained in the presence of microglia (Fig. 2.5E-G, and 
magnified in F1 and G1). These plaques displayed an irregular shape with structured 
filaments radiating out from a central fissure/point and lacked the homogenous staining 
intensity of plaques in microglia-intact 5xfAD mice. As such, both plaque circularity (Fig. 
2.5H) and mean Thio-S intensities (Fig. 2.5I) were significantly reduced in the 5xfAD 
mice devoid of microglia. These features were common to all areas explored, including 
in the subiculum, where some IBA1+ cells were still present, suggesting that a threshold 
density of microglial cells is required for full plaque compaction/restructuring. Dystrophic 
neurites are found in a halo around fibrillar plaques and are characterized by the 
Figure 2.5: Microglia facilitate plaque formation and compaction. A, B, Representative 
hemisphere stitches of 5xfAD and 5xfAD + PLX5622 mice stained for dense-core plaques (Thio-S in 
green) and immunolabeled for microglia (IBA1 in red). Confocal images of subicula (A1 and B1) 
stained with Thio-S for dense core plaques (green) and immunolabeled with IBA1 for microglia (red) 
and 6E10 for diffuse plaques (blue). C, Quantification of IBA1+ cells in the subiculum revealed an 
increase in 5xfAD mice compared to wild-type (p<0.001). PLX5622 treatment reduces IBA1+ cell 
number in wild-type and 5xfAD groups by 99% (p<0.001) and 77% (p<0.001), respectively. Two-way 
ANOVA with Tukey’s post hoc test; n = 7 for Wild-type, n = 6 for PLX5622, n = 6 for 5xfAD, n = 6 for 
5xfAD + PLX5622. D, Plaque number within the subiculum is reduced by 33% in 5xfAD + PLX5622 
mice compared to 5xfAD animals (p<0.001). Two-tailed independent t-test; n = 6 for 5xfAD, n = 6 for 
5xfAD + PLX5622. E-G, Confocal images of dense-core plaques (Thio-S in green) and microglia 
(IBA1 in red) in the cortex, thalamus, and subiculum, respectively, of both 5xfAD groups showing an 
alteration in plaque morphology with CSF1R inhibitor treatment. Zoomed images of dense-core 
plaques (Thio-S in green) in the thalamus (F1) and subiculum (G1) of 5xfAD and 5xfAD + PLX5622 
mice. H-I, Plaque circularity and Thio-S fluorescence intensity is decreased by ~30% with PLX5622 
treatment in 5xfAD mice compared to untreated 5xfAD animals (p<0.001 for both), respectively. Two-
tailed independent t-test; n = 6-7 for 5xfAD, n = 6 for 5xfAD + PLX5622. J-K, Images of subicula 
stained for dense-core deposits with Thio-S and immunolabeled for dystrophic neurites with LAMP1 
(in red) or APP (in red), respectively. Zoomed images of plaque-associated dystrophic neurites (J1 
and K1) in PLX5622-treated 5xfAD animals. L-M, Quantification of LAMP1 and APP immunoreactive 
dystrophic neurites, showing a ~50% (p=0.020) and ~100% (p=0.068) increase with microglial 
elimination in 5xfAD animals, respectively. Two-tailed independent t-test; n = 5 for 5xfAD, n = 4-5 for 
5xfAD + PLX5622. Statistical significance is denoted by *p<0.05, **p<0.01, and ***p<0.001. Statistical 
trends are denoted by #p<0.10. Error bars indicate SEM. 
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accumulation of LAMP1 and APP223,224. To evaluate the role of microglia in regulating 
the growth of dystrophic neurites, we stained for LAMP1 and APP (Fig. 2.5J-K) and 
found that the absence of microglia enhanced the dystrophic neurite halo area (Fig. 
2.5L, M). These results fully confirm prior studies showing that microglia form a physical 
barrier around plaques and compact Aβ into dense deposits, protecting against local 
neurite damage91,116-118,225,226. 
 
Microglia incorporate free A into plaques, facilitating growth, in 5xfAD animals 
The plaques that we observe in CSF1R inhibitor treated 5xfAD mice likely result from 
surviving microglia at the time of plaque onset (i.e., Fig. 2.2C, E), which die with further 
CSF1R inhibitor treatment, after the plaque is formed (i.e., Fig. 2.3D-K). Notably, we 
find these plaque volumes are smaller (Fig. 2.3N), suggesting that seeded plaques 
subsequently failed to expand/grow in the absence of microglia. To explore if microglia 
play a role in the growth of dense core plaques, we infused fluorescently-labeled A1-42 
into the cortex of 5xfAD animals, evaluating the ability of free A to incorporate into 
existing plaques in the presence or absence of microglia. Three-month-old 5xfAD 
animals, an age of rapid plaque growth and spreading, were treated with control or 
PLX3397 (600ppm in chow) for 2 weeks to eliminate microglia. At this time, mice 
received a single cortical injection of fluorescently-labeled A1-42 and were euthanized 
one week later (see schematic, Fig. 2.6A). Quantification of Thio-S+ plaque volumes 
revealed a significant reduction following the elimination of microglia (Fig. 2.6F), 
confirming that microglia are promoting the expansion/growth of plaques. In untreated 
5xfAD animals, we found that the infused A1-42 was restricted to the Thio-S+ plaque 
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core (Fig. 2.6B, D), demonstrating that free A becomes fully incorporated into the 
fibrillar core in the presence of microglia. In the absence of microglia, fluorescent A1-42 
does not fully incorporate into the dense core, instead forming a distinct halo around the 
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Thio-S+ plaque core (Fig. 2.6D, E). Accordingly, quantification revealed a stark increase 
in fluorescently-labeled A1-42 associated with Thio-S+ plaques in the absence of 
microglia (Fig. 2.6G, H). Thus, arresting plaque growth with microglia elimination (seen 
via changes in Thio-S+ plaque volume and fluorescently-labeled A1-42 incorporation) 
indicates that these cells incorporate free A1-42 into the fibrillar plaque core, facilitating 
plaque growth.  
 
Replication of diminished plaque formation with an alternative CSF1R inhibitor 
Given the striking effects of PLX5622 treatment/microglial depletion on reducing plaque 
formation, we wanted to confirm the results with alternative CSF1R inhibitor paradigms. 
We established that PLX3397 formulated at 600 ppm in chow could achieve robust 
brain-wide microglial elimination (>99%)227, and thus, treated 1.5-month-old 5xfAD mice 
with this formulation until 5 months of age (Fig. 2.7A).  Again, examination of the brains 
of these treated mice showed minimal plaque pathology and the appearance of CAA 
(Fig. 2.7C, D). We further examined the role of peripheral CSF1R inhibition on AD 
pathology by treating 1.5-month-old 5xfAD mice for 5 months with PLX3397 (75 ppm) 
chow (Fig. 2.7A) – a formulation that provides robust peripheral CSF1R inhibition 
Figure 2.6: Microglia deposit available A into the plaque core. A, Experimental design. B,C, 
Representative images of the somatosensory (SS) cortex injected with fluorescently-labeled A1-42 
(blue) and stained for dense-core deposits (Thio-S in green) and  microglia (IBA1 in red).  D,E, 
Zoomed images of fluorescently-labeled A1-42 (blue) bound to dense-core plaques (Thio-S in green). 
F, Quantification of Thio-S plaque volumes in 5xfAD and 5xfAD mice treated with PLX3397, showing 
a ~50% reduction in the size of dense-core deposits with microglia elimination (p=0.0105). G, A1-42 
volume increased ~170% in the absence of microglia (p=0.0581), resulting in the appearance of a 
halo surrounding dense-core plaques.  H, The ratio of A1-42 volume to Thio-S volume in microglia-
intact and -devoid 5xfAD animals shows a ~300% increase with PLX3397 treatment (p=0.0030). 
Statistical significance is denoted by *p<0.05, **p<0.01, and ***p<0.001. Statistical trends are denoted 
by #p<0.10. Error bars indicate SEM; (n=4-5/group; 58 plaques for 5xfAD; 53 plaques for 5xfAD + 
PLX3397). 
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without microglial elimination133. This lower dose achieved brain levels of ~ 1 μM, 
compared to ~ 10 μM with the higher dose (Fig. 2.7B), and accordingly, microglia 
numbers were unchanged relative to untreated animals (Fig. 2.7E-I). With 75 ppm 
PLX3397, no reductions in plaque load or appearance of CAA were detected in treated 
5xfAD animals compared to controls (Fig. 2.7E-K).  Thus, peripheral CSF1R inhibition 
or simply the presence of CSF1R inhibitor within the CNS do not attribute to the 
reductions in plaque pathology and more complete microglial elimination is necessary to 
perturb plaque formation processes. 
 
Gene expression analyses of Wild-type and 5xfAD mice in the presence and 
absence of microglia, across brain regions: 
Given the prolonged absence of microglia throughout the adult life of wild-type and 
5xfAD mice, the stark reduction in plaque formation in the absence of microglia, and the 
differences in pathology deposition and microglial number in various brain regions (i.e., 
no plaques but CAA in cortex, plaques but no microglia in thalamus and 
hippocampus/subiculum), we explored alterations in regional gene expression (mice 
treated through 1.5-7 months of age). To that end, brains were microdissected into 
cortical, hippocampal, and thalamic+striatal regions. RNA was extracted,and 
Figure 2.7: Administration of an analogous CSF1R inhibitor, PLX3397 (75 ppm and 600 ppm), 
to 5xfAD mice. A, Experimental design. B, Terminal PK of wild-type and 5xfAD groups treated with 
PLX3397. C-D, Confocal images of tissue stained for dense-core plaques (Thio-S in green) and 
immunolabeled for microglia (IBA1 in red) in 600 ppm PLX3397-treated and control mice. E-H, 
Sections of the retrosplenial (RS) and somatosensory (SS) cortex, respectively, stained for dense-
core plaques (Thio-S in green) and immunolabeled for microglia (IBA1 in red) in mice treated with 
control or 75 ppm PLX3397. I, Quantification of IBA1+ cell number in the RS and SS cortex. Two-way 
ANOVA with Tukey’s post hoc test; n = 4 for W ild-type, n = 6 for PLX3397, n = 6 for 5xfAD, n = 4 for 
5xfAD + PLX3397. J-K, Quantification of cortical plaque number and volume, respectively, revealing 
no change in these measures with 75 ppm PLX3397 treatment in 5xfAD mice. Two-tailed 
independent t-test; n = 4-5 for 5xfAD, n = 4-5 for 5xfAD + PLX3397. Statistical significance is denoted 
by *p<0.05. Statistical trends are denoted by #p<0.10. Error bars indicate SEM. 
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Figure 2.8 Principal component analysis of RNA-seq data. Principal component analysis of log 
counts per million mapped reads for each of the 12 groups (Wild-type Cortex, Hippocampus, and 
thalamus; PLX5622 Cortex, Hippocampus, and thalamus; 5xfAD Cortex, Hippocampus, and 
thalamus; and 5xfAD + PLX5622 Cortex, Hippocampus, and thalamus), after filtering genes that were 
not expressed and normalizing gene expression distributions. Groups denoted by color and arrows. n 
= 4 for all groups. 
subsequently analyzed by RNA-seq (n=4/group; Fig 2.8). A searchable database of all 
RPKM values can be found at 
https://rnaseq.mind.uci.edu/green/ad_plx/gene_search.php.  
 
Extensive microgliosis across all brain regions in 5xfAD mice: To assess the global 
effects of pathology on gene expression, we compiled a list of genes significantly 
changed (using raw p-values) in all 3 brain regions in 5xfAD vs. wild-type mice (Fig. 
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2.9A). All common genes were upregulated and the vast majority are microglia-
associated, reflecting the microgliosis occurring in 5xfAD mice. The elevation levels 
averaged 1-fold-change higher across all homeostatic microglial genes, consistent with 
the observed increase in microglial numbers (Fig. 2.2F). Consistent with these genes 
being predominantly expressed by microglia, their expression was markedly reduced 
with treatment in either 5xfAD or wild-type mice. We selected a subset of homeostatic 
microglial genes (Csf1r, Cx3cr1, C1qa, Hexb, Siglech, and Spi1) and displayed the 
expression (RPKM) values for each of the brain regions (Fig. 2.9B). The expression of 
these genes was nearly undetectable from PLX5622-treated mice, highlighting their 
specific expression by microglia and the specificity of PLX5622 on microglial survival.  
Of note, the expression of homeostatic microglial genes was higher in the 5xfAD + 
PLX5622 hippocampus than other microdissected brain regions (or wild-type mice), 
reflecting the population of surviving microglia identified in the subiculum (Fig. 2.5B1). 
Next, we sought to characterize the gene expression profile of the surviving, plaque-
forming microglia in treated 5xfAD animals. To that end, we searched for genes 
upregulated in 5xfAD brains that were subsequently downregulated with PLX5622 
treatment (to select for microglia-expressed genes) but not present in wild-type brains. 
We identified expression of Ccl6, Clec7a, Cst7, Ctsd, Ctsz, and Itgax as main genes 
Figure 2.9: Remaining plaque-forming microglia in the microdissected hippocampus exhibit a 
DAM expression profile. A, All gene expression changes where p<0.05 for Wild-type (WT) vs. 5xfAD 
in all three brain regions shown as Log(2) fold change for each gene, for the 9 relevant comparisons 
(5xfAD vs. WT in cortex, hippocampus, or thalamus, 5xfAD + PLX5622 vs. 5xfAD in cortex, 
hippocampus, or thalamus, and WT + PLX5622 vs. WT in cortex, hippocampus, or thalamus). B, 
RPKM values shown for a subset of the homeostatic microglial genes from (A), including Csf1r, 
Cx3cr1, C1qa, Hexb, Siglech, and Spi1. C, RPKM values shown for a subset of the disease-
associated microglial genes from (A), including Ccl6, Clec7a, Cst7, Ctsd, Ctsz, and Itgax. RPKM 
values for all genes/brain regions can be found at 
https://rnaseq.mind.uci.edu/green/ad_plx/gene_search.php. n = 4 per group for all analyses. Error 
bars indicate SEM. 
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that follow this expression pattern (Fig. 2.9C), as well as Asb10, B2m, 
Ccl3, Ch25h, Gpr65, Grn, Hcar2, Hexa, Ly9, Lyz2, Oasl2, Pdcd1, Plcg2, and Treml2. 
Notably, several of these genes are known markers of disease-associated microglia83 
(DAM). Consistent with our expectations, these genes were present in PLX5622-treated 
5xfAD hippocampus (but not cortex or thalamus), reflecting the population of surviving 
microglia in this region (see images of subicula in Fig. 2.5A1, B1, which are included in 
microdissected hippocampi) and providing a gene expression signature of plaque-
forming/associated microglia.  
 
Microglia mediate the downregulation of synaptic genes in the hippocampus:  We 
compared the number of differentially expressed genes (adjusted p-values <0.05) 
induced by AD pathology in each of the three microdissected brain regions (i.e., wild- 
both cortex and thalamus exhibited fewer changes in gene expression (141 and 107 
type vs. 5xfAD) and found that the hippocampus was most impacted (414 genes), while 
both cortex and thalamus exhibited fewer changes in gene expression (141 and 107 
genes respectively; Fig. 2.10A). Transgene expression in 5xfAD mice (consisting of 
App, Psen1, and Thy1) was increased by ~2-fold over endogenous expression across 
brain regions (Fig. 2.10B) and was not impacted by treatment, consistent with the 
protein expression data (Fig. 2.4K, L). Initially focusing on the 414 gene expression 
changes in the hippocampus induced by pathology, we plotted a heat map of the log(2) 
fold change for each of the 9 relevant comparisons (5xfAD vs. wild-type, 5xfAD + 
PLX5622 vs. 5xfAD, and PLX5622 vs. wild-type, each for cortex, hippocampus, and 
thalamus; Fig. 2.10C). The hippocampus displayed a unique gene expression profile 
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relative to the cortex and thalamus and included a unique subset of downregulated 
genes. Of note, only 1 downregulated gene was identified in the cortex and none were 
detected in the thalamus. Furthermore, all gene expression changes (either upregulated 
or downregulated) appeared to be fully reversed in the hippocampus of treated 5xfAD 
mice, with fold-changes in 5xfAD + PLX5622 vs. 5xfAD hippocampus being equal and 
opposite to those induced in the 5xfAD mice (highlighted by red border). Of the 414 
identified genes, 77 were down-regulated in the 5xfAD hippocampus (Fig. 2.10C, and 
individual genes plotted in D). Notably, these genes were primarily synaptic- and 
neuronal-associated genes such as Dlk2, Dync1l1, Gls, Kcnq3, Nrg3, and Scn1b. 
Importantly, the absence of microglia prevented the AD-pathology induced 
downregulation of neuron-associated genes (Fig. 2.10E), highlighting that microglia in 
the 5xfAD brain drive the downregulation of plasticity-related genes in the hippocampus. 
Enrichment analyses of the hippocampus revealed an upregulation in immune function-
Figure 2.10: Microglia mediate downregulation of neuronal/plasticity genes in the 
hippocampus in response to AD pathology. A, Venn diagram showing the number of differentially 
expressed genes (adjusted p <0.05) for cortex, hippocampus, and thalamus for wild-type (WT) vs. 
5xfAD mice. B, Heatmap of the p-value and log(2) fold change for all 9 comparison groups (5xfAD vs. 
WT in cortex, hippocampus, or thalamus, 5xfAD + PLX5622 vs. 5xfAD in cortex, hippocampus, or 
thalamus, and WT + PLX5622 vs. WT in cortex, hippocampus, or thalamus), as well as 3 
comparisons between brain regions for both WT and 5xfAD mice, for the transgene components in 
5xfAD mice (App, Psen1, Thy1). C, Heatmap of all 413 gene expression differences identified in the 
hippocampus for wild-type vs. 5xfAD, expressed as log (2) fold change, and all 9 comparison groups 
included. Hippocampus for 5xfAD vs. WT and 5xfAD + PLX5622 vs. 5xfAD highlighted by red border, 
showing that most significant gene expression changes induced by pathology do not occur in the 
absence of microglia. D, Downregulated genes in the hippocampus from (A), displayed as a heatmap 
of log(2) fold change differences for all 9 comparisons, showing that the same genes are not 
downregulated in the absence of microglia (5xfAD + PLX5622 vs. 5xfAD Hip). E, RPKM values 
plotted on a log(2) scale for a subset of plasticity genes from (D).  F, The top 5 significantly 
upregulated and downregulated pathways for 5xfAD vs. wild-type hippocampus (red), along with 
respective -log(10) p-values plotted: most upregulated pathways are related to immune function, 
while downregulated pathways are mainly associated with neuronal and synaptic activity. The same 
pathways are displayed for the comparison between 5xfAD + PLX5622 vs. 5xfAD hippocampus 
(yellow), showing that the absence of microglia prevents the upregulation of immune pathways and 
the downregulation of synaptic pathways. Expression difference denoted by *. Log(2) fold change and 
p-values indicated by respective scale bar. n = 4 per group for all analyses. Error bars indicate SEM. 
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associated pathways in 5xfAD vs. wild-type, and accordingly, these pathways were all 
highly significantly downregulated with PLX5622 treatment (Fig. 2.10F). Analyses of 
downregulated pathways in 5xfAD vs. wild-type hippocampi revealed that the most 
highly significant pathways were related to neuronal functioning, such as glutamate 
receptors, synaptic vesicles, and neuronal membranes (Fig. 2.10F). Importantly, many 
of these pathways were upregulated – or more accurately, never downregulated – with 
the absence of microglia (Fig. 2.10F), indicating that microglia influence neuronal gene 
expression pathways in response to AD pathology.  
 
Neither AD pathology nor treatment/absence of microglia grossly modulate AD-related 
gene expression:  Although we confirmed that the absence of microglia/treatment with 
PLX5622 did not alter the amount of Aβ produced, we wanted to explore the impact of 
pathology and microglia on genes associated with APP processing, Aβ clearance and 
metabolism, and AD in general (Fig. 2.4M). The only significant changes in gene 
expression in 5xfAD mice compared to wild-type were the upregulation of the 
transgenes (App and Psen1; as expected due to overexpression), and Apoe, all of 
which were not altered by the absence of microglia, and the downregulation of myeloid-
expressed Trem2, Ctsb, Ctsc, and Ctsd in the absence of microglia, as expected. 
Comparisons of changes in expression between brain regions showed regional 
differences in Ache, Apoe, Ptk2b, Sorl1, and Sort1. Thus, both AD pathology and the 
absence of microglia have minimal effects on AD-related genes, and importantly, we 
observe no alterations in gene expression or protein production in the absence of 
microglia that could account for reduced plaque formation. 
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Repopulation of microglia seed plaques 
While microglia can be indefinitely depleted via the continued administration of CSF1R 
inhibitors, the microglial compartment can also be repopulated upon CSF1R inhibitor 
withdrawal36,133,228. To further prove that microglia are responsible for plaque formation, 
we sought to examine the effects of microglial repopulation in 5xfAD mice after 10 
weeks of PLX5622 treatment. We treated a cohort of 1.5-month-old 5xfAD mice with 
PLX5622 (1200 ppm in chow) to eliminate microglia until 4 months of age, then CSF1R 
inhibitor-formulated chow was removed to stimulate microglial repopulation and the 
brains were examined 1 month later (Fig. 2.11A). Microglia repopulated all areas of the 
brain in both wild-type and 5xfAD mice (Fig. 2.11B), although overall densities were 
lower than the untreated mice in cortical regions (Fig. 2.11C, D; quantified in F). As 
demonstrated previously, untreated 5xfAD mice exhibit cortical plaques at 4 months of 
age, but 5xfAD mice devoid of microglia show reduced plaque formation (Fig. 2.3C, F, 
L). Furthermore, from our extended cohort of 5xfAD mice devoid of microglia, we know 
that plaque formation is severely diminished in treated 5xfAD animals, even by 7 
months of age (Fig. 2.3E, H). However, examination of microglia-repopulated 5xfAD 
brains revealed the appearance of robust plaque pathology (Fig. 2.11D) with plaque 
numbers being equal to the untreated 5xfAD mice (Fig. 2.11G), although average 
plaque volumes were smaller (Fig. 2.11H). Notably, vascular pathology was still present 
in the repopulated brains (Fig. 2.11D), showing that the reintroduction of microglia does 
not reverse the vascular deposition of A, at least within this one-month timeframe. 
Repopulating microglia associate with the new plaques but do not appear to react to the 
vascular deposits (Fig. 2.11E). Moreover, GFAP+ astrocytes associated with plaques in 
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both control and repopulated 5xfAD brains (Fig. 2.11I, J), but were absent in 5xfAD 
brains devoid of microglia. Thus, the reintroduction of microglia in the 5xfAD brain via 
CSF1R inhibitor withdrawal coincides with a full restoration of plaque pathology and 
directly implicate the reappearance of microglia in the brain with the seeding and 
formation of plaques. 
 
DISCUSSION 
In this study, we sought to investigate the role of microglia throughout the onset and 
development of AD pathology in 5xfAD mice, requiring the sustained depletion of 
Figure 2.11: Microglia seed plaques. All analyses listed in respective order for retrosplenial (RS) 
cortex, somatosensory (SS) cortex, and thalamus. A, Experimental design: 1.5-month-old wild-type 
(WT) and 5xfAD mice were administered PLX5622 (1200 ppm in chow) until 4 months of age to 
eliminate microglia and PLX5622 diet was subsequently withdrawn for 1 month to allow microglial 
repopulation. B, Representative hemisphere stitches of sections stained for dense core plaques (Thio-
S in green) and immunolabeled for microglia (IBA1 in red). C-E, Cortical images of dense-core plaque 
staining (Thio-S in green) and microglia immunolabeling (IBA1 in red). F, Quantification of IBA1+ cell 
number revealed an increase in the 5xfAD group compared to WT (p=0.001, NS, p<0.001). PLX5622-
treatment reduced microglial numbers in both WT (p<0.001, p<0.001, p<0.001) and 5xfAD animals 
(p<0.001, p<0.001, p<0.001). Repopulated groups showed an increase in microglial number 
compared to PLX5622-treated groups in both WT (NS, p=0.054, p=0.008) and 5xfAD animals 
(p=0.006, p<0.001, p<0.001). Microglial numbers in repopulated groups of WT (NS, p=0.002, NS) and 
5xfAD (p<0.001, p<0.001, p=0.027) animals were ~50% of untreated mice in the cortex. Two-way 
ANOVA with Tukey’s post hoc test; n = 5 for Wild-type, n = 4 for PLX5622, n = 4 for Wild-type + 
Repopulation, n = 8 for 5xfAD, n = 9 for 5xfAD + PLX5622, n = 6 for 5xfAD + Repopulation. G, Thio-S+ 
plaque number was significantly reduced in 5xfAD + PLX5622 mice compared to the 5xfAD group 
(p<0.001, p<0.001, p=0.007). Compared to 5xfAD animals devoid of microglia, the 5xfAD + 
Repopulation group showed significantly elevated plaque numbers (p<0.001, p<0.001, p=0.001). 
Repopulation in 5xfAD mice restored plaque numbers to that of untreated 5xfAD mice (NS, NS, NS). 
NS, not significant. One-way ANOVA with Tukey’s post hoc test; n = 7 for 5xfAD, n = 9 for 5xfAD + 
PLX5622, n = 6 for 5xfAD + Repopulation. H, Cortical plaque volume was reduced by ~20% with 
microglia repopulation in 5xfAD mice compared to untreated 5xfAD mice (p=0.048). Two-tailed 
independent t-test; n = 7 for 5xfAD, n = 6 for 5xfAD + Repopulation. I, Confocal images of cortical 
sections stained for dense-core plaques (Thio-S in blue) and immunolabeled for astrocytes with GFAP 
(in green) and S100β (in red). J, Quantification of the number of GFAP+ astrocytes in the SS cortex. 
GFAP number was increased in 5xfAD animals relative to untreated mice (p=0.010) and PLX5622 
treatment in 5xfAD mice normalized GFAP cell number (p=0.002). Microglia repopulation in 5xfAD 
animals restored astrocyte reactivity (p<0.001), and increased GFAP cell number relative to WT 
repopulated mice (p=0.009). Two-way ANOVA with Tukey’s post hoc test; n = 4 for Wild-type, n = 4 for 
PLX5622, n = 4 for Wild-type + Repopulation, n = 7 for 5xfAD, n = 10 for 5xfAD + PLX5622, n = 6 for 
5xfAD + Repopulation. Statistical significance is denoted by *p<0.05, **p<0.01, and ***p<0.001. Error 
bars indicate SEM.  
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microglia from the adult mouse brain for a period of ~6 months. While various methods 
of microglial ablation are available, the extent/duration of microglial depletion and the 
technical requirements necessary to achieve sustained microglial elimination prohibit 
the use of most depletion paradigms. For example, the CX3CR1creER x DTRff mouse 
model relies on administration of diphtheria toxin, which not only induces a cytokine 
storm, but also limits microglial elimination to 5 days120. The CD11b-HSVTK model 
requires intracerebroventricular infusion of ganciclovir in order to produce substantial 
microglial depletion, which in turn induces BBB damage and myelotoxicity, resulting in 
increased mortality following 4 weeks of ganciclovir treatment104. Clodronate liposome 
administration is also reported to deplete microglia, however, this effect is short-lived 
and requires intrahippocampal infusion, as clodronate liposomes are incapable of 
crossing the BBB121. Previously, we discovered that microglia are critically dependent 
upon CSF1R signaling for their survival133 and that CSF1R inhibitors serve as effective 
tools to achieve microglial depletion. In contrast to other methods, CSF1R inhibitors 
provide the following advantages: 1) their administration is non-invasive, 2) they do not 
rely on other pharmacological drivers such as ganciclovir or tamoxifen, 3) they do not 
induce an inflammatory response (cytokine storm) from the surviving cells, 4) they have 
highly selective effects on microglia, 5) they can be formulated to control for peripheral 
myeloid effects on microglial responses, and 6) they can be used clinically, and 
therefore, experimental findings are potentially translatable. Most importantly, CSF1R 
inhibition is the only currently available method capable of achieving sustained long-
term microglial elimination. Using PLX5622, we were able to eliminate >95% of 
microglia from the brains of 5xfAD mice prior to and during the formation of AD 
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pathology, even up to 6 months of duration, and elucidate their roles in plaque 
formation. Data presented here show that long-term PLX5622-mediated microglial 
depletion is highly robust, sustainable, and specific to the microglial compartment. 
These findings are demonstrated by extensive gene expression analyses, a lack of 
behavioral/cognitive impairments, and unaffected circulating immune cell numbers. 
Together, these data demonstrate that PLX5622 is a useful compound for investigating 
microglial dynamics.  
The genetics of familial AD indicate that altered APP processing and plaque 
accumulation are critical for disease etiology229. In sporadic AD, plaques appear in the 
brain prior to any other overt pathologies199 and precede cognitive deterioration and 
disease progression230-232. AD appears to be precipitated by the formation and 
development of plaques in the brain, and therefore, identifying the underlying biology of 
plaque formation is crucial to understanding and preventing disease onset. Genome-
wide association studies have identified several genes associated with an increased risk 
for developing sporadic AD. Many of these risk variants are highly enriched in myeloid 
cells201, indicating that myeloid biology appears to be a large contributor to the 
development of disease. Microglia are the resident myeloid cell of the CNS, and their 
activated presence surrounding plaques is a prominent feature of AD pathology. While 
microglia are phagocytes, in the later stages of disease, studies indicate that these cells 
do not clear Aβ or modulate plaque numbers/sizes in the brain104,115,132. Instead, 
evidence indicates that they play a role in synaptic damage and neuronal loss132,198,233. 
Examination of human brains (non-demented, high pathology non-demented, and 
Alzheimer’s disease subjects), as well as mouse models of AD, reveal the accumulation 
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of A aggregates within the lysosomes of microglia unassociated with plaques. Thus, 
we hypothesized that neuronally-derived A is internalized/aggregated within microglia, 
and that this material contributes to the initial formation of plaques. In a prior study, we 
evaluated the contributions of microglia in an advanced stage of AD, by eliminating 
microglia in aged (i.e., 10-month-old) 5xfAD mice that had developed extensive plaque-
related pathologies. We found that the elimination of microglia prevented synaptic and 
neuronal loss, without affecting plaque deposition or A levels in the brain132.  
Subsequent studies confirmed the critical roles of microglia to neuronal loss234, 
highlighting the deleterious actions of chronically activated microglia in the advanced 
stages of AD. In this study, we sought to identify whether microglia play a role in the 
initial deposition of plaques, via sustained treatment with PLX5622 prior to and during 
the period of plaque formation in the 5xfAD mouse model of AD. Here, we find that 
plaque formation is prevented in the absence of microglia, even over extended periods 
of time. While some plaques form in specific brain areas with treatment, we find that 
these few remaining plaques are associated with a small subset of microglia initially 
resistant to CSF1R-inhibition. These microglia are most apparent in the thalamus, 
retrosplenial cortex, and subiculum. Once formed, these plaques persist thereafter, 
even long after plaque-associated microglia are eliminated. Thus, our work 
demonstrates that plaque onset relies on the presence and activity of microglia. 
Additionally, as some microglia survive CSF1R inhibitor treatment, this approach also 
allows for the exploration of these remaining cells in plaque structure and maintenance. 
Insights into the roles of microglia in plaque biology have been explored via the study of 
the myeloid gene Trem2, in which coding mutations, presumed to be loss of function, 
90 
 
are associated with increased risk of sporadic AD235-237. Recently, it was demonstrated 
that perturbation of Trem2 signaling impaired the association of microglia with 
plaques91,116,238, revealing that plaque-associated microglia compact plaque cores and 
form a barrier that protects surrounding neurites from toxicity91,116,117. In line with these 
studies, we confirm and demonstrate that plaque compaction and barrier formation are 
natural functions of microglia in disease, rather than functions conferred by the loss of 
TREM2 function. In addition, we show that microglia are necessary for the development 
of the plaques. These findings are supported by recent data showing that plaque 
seeding is accelerated in Trem2 knockout mice82, suggesting that the microglial function 
involved in the initial formation of plaques is related to TREM2 signaling.  
By way of further mechanism for plaque seeding and growth, microglia could be: 1) 
secreting factors that facilitate Aβ fibrillization50, 2) physically forming plaque cores from 
extracellular Aβ via compaction239, or 3) ingesting, aggregating, and modifying  
extracellular Aβ internally, which is eventually released to seed plaques, in line with in 
vitro data240. Indeed, we observe aggregated A within ramified microglia distal to 
plaques in two different mouse models of AD (Fig. 2.1A-F), as well as the human brain 
(Fig. 2.1K-O). This observation is seemingly contrary to the idea that the source of 
internalized microglial A is plaque-derived. In accordance, we find that plaque growth 
ceases in the absence of microglia, suggesting a mechanism by which microglia deliver 
Aβ to the plaque seed/core. These data suggest that following the uptake of freely 
available A, microglia subsequently deposit aggregated A into the extracellular space, 
thus contributing to the formation of plaques.  
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Together, these results demonstrate that plaque formation does not result from impaired 
microglial clearance, but rather requires the action(s) of microglia – an observation that 
may explain the overrepresentation of microglia-expressed genes in AD genome-wide 
association studies. In line with this, modulation of ApoE4 signaling prior to the period of 
plaque deposition alters Aβ accumulation, whereas intervening after the emergence of 
plaques has no effect225,241. Notably, the manipulation of ApoE in AD mouse models 
phenocopies the absence of microglia (i.e. CAA instead of plaques242-244). Hence, it 
appears that the presence of microglia is necessary and integral for the formation of 
plaques, similar to elevated brain Aβ42/Aβ40 ratios245,246 and the presence of ApoE, in 
disease243. Of particular note, in the absence of microglia, Aβ accumulates not in the 
parenchymal space, but instead within cortical blood vessels as CAA, suggesting that 
microglia may play a role in shuttling Aβ away from the vasculature. Thus, it could be 
possible that microglia protect against CAA via the formation of parenchymal plaques. 
As 5xfAD mice overexpress APP/Aβ, it is unknown whether the experimentally 
observed accumulation of A in blood vessels is physiologically relevant. It is not 
detected in untreated 5xfAD mice containing microglia nor wild-type mice devoid of 
microglia. Interestingly, this phenotype is akin to Aβ immunotherapy studies in mice and 
humans, in which clearance of parenchymal plaques is accompanied by Aβ deposition 
in blood vessels247-249. Since low CNS exposure of PLX3397 (~1μM) does not modulate 
microglia, plaques, or induce CAA, we conclude that the appearance of CAA is not due 
to peripheral effects of the drug, but is in fact dependent on microglial elimination.  
To further delineate microglial roles, we performed gene expression analyses of wild-
type and 5xfAD mice in cortex, hippocampus, and thalamus, in both microglia-intact 
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animals and mice lacking microglia for the entirety of their adult lives. Notably, we find 
hippocampal gene expression is greatly influenced by the presence of AD pathology 
relative to the cortex and thalamus, despite abundant plaque load in all these regions. 
Differential gene analysis revealed that nearly all significantly altered genes, in 5xfAD 
compared to WT mice, were associated with microgliosis in the cortex and thalamus, 
while the hippocampus displayed reductions in gene expression associated with 
neuronal and synaptic function. The absence of microglia prevented many of these 
changes in 5xfAD mice, despite the continued presence of hippocampal plaques, due to 
a small population of surviving myeloid cells in the subiculum. Although plaque-
associated microglia may protect against local neurite damage, the presence of 
microglia is also required for the reduction in expression of synaptic and neuronal genes 
in the hippocampus associated with AD. Notably, the absence of microglia is not 
associated with detectible alterations in immune- and synapse-related genes, 
suggesting that microglia mediate most AD pathology-induced changes in gene 
expression. Therefore, microglia appear to have detrimental and beneficial roles in a 
preclinical model of AD. Whether these effects are stratified into separate populations 
(i.e., protective effects of plaque-associated microglia vs. harmful effects of non-plaque 
associated microglia, as recently suggested83) needs to be determined. In support of 
discrete microglial populations mediating dichotomous effects, we show that the 
elimination of 88% of non-plaque associated microglia and presence of ~50% of plaque-
associated microglia in 5xfAD mice with existing pathology using our CSF1R inhibitor 
treatment paradigm resulted in the prevention of both synaptic and neuronal loss132. 
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These findings highlight detrimental functions of non-plaque-associated microglia and 
beneficial roles of plaque-associated microglia. 
In conclusion, we have designed and created a specific CSF1R inhibitor, PLX5622, that 
allows for the sustained and specific elimination of microglia. This novel method of 
microglial depletion provided us with the means to eliminate microglia for the duration of 
AD pathogenesis. Ultimately, these data demonstrate that microglial elimination is 
associated with the prevention of plaque formation and the downregulation of 
hippocampal neuronal genes that occur in a preclinical mouse model of AD. These 
results indicate that microglia appear to contribute to multiple facets of AD etiology – 
microglia appear crucial to the initial appearance and structure of plaques, and following 
plaque formation, promote a chronic inflammatory state modulating neuronal gene 
expression changes in response to Aβ/AD pathology.  
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CHAPTER THREE 
Evaluating microglial ApoE as a contributor to plaque formation 
 
INTRODUCTION 
In chapter two, we show that an absence of microglia before and during the normal 
period of plaque development prevents cortical parenchymal plaque formation, and 
instead, shifts Aβ deposition to the vasculature. Modulation of ApoE signaling, the 
strongest identified genetic risk factor for the development of AD, bears a striking 
similarity to this phenotype242,244,250-252. The brains of mice with knocked-in human 
ApoE3 or ApoE4 show a dramatic reduction in parenchymal plaque deposits, and a shift 
in pathology to the vasculature242,244, whereas complete knockout of ApoE signaling 
inhibits plaque formation118,243,253. Additionally, reductions in ApoE signaling prior to the 
period of plaque deposition prevents A accumulation, whereas its reduction after the 
emergence of plaques had no effect225,241. These observations resemble the effects of 
microglial elimination in AD – the data in chapter two demonstrate that the elimination of 
microglia prior to plaque onset also prevents plaque formation, whereas the elimination 
of microglia subsequent to plaque onset bears no effect on plaque burden132. Together, 
these data highlight potential overlapping pathways between microglia-eliminated AD 
brains and mouse models modulating ApoE expression that could underlie plaque 
pathogenesis. 
While predominantly expressed by astrocytes254, ApoE expression can be induced in 
microglia in disease states81,83,119,255, including data from chapter one that shows a 
~20% contribution of microglia to the total pool of measured ApoE transcripts in AD (Fig. 
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1.6A132). In the AD brain, ApoE expression is highly enriched in plaque-associated 
microglia82,83,119 and dense core A deposits82. Given the phenotypic parallels between 
pathology in contexts of both microglial or ApoE loss, we set out to understand whether 
microglial ApoE plays a crucial role in the seeding of plaques. To that end, we 
selectively knocked-out ApoE from microglia/myeloid cells in 5xfAD mice, allowing us to 
determine the contribution of microglial ApoE to plaque formation. We find that in the 
absence of microglial ApoE signaling, plaque numbers and volumes in the subiculum of 
5xfAD mice are reduced relative to ApoE-intact 5xfAD animals, identifying ApoE 
signaling as a driver of plaque formation. 
 
MATERIALS AND METHODS 
Compounds: PLX5622 was formulated in AIN-76A standard chow by Research Diets 
Inc. at 1200 ppm. 
 
Animal Treatments: All rodent experiments were performed in accordance with animal 
protocols approved by the Institutional Animal Care and Use Committee at the 
University of California, Irvine. B6.129S6-Apoe tm1.1Mae/MazzJ (Apoe f l / f l; stock no. 
028530) and FVB-Tg(Csf1r-icre)1Jwp/J (CSF1R-Cre+/-; stock no. 021024) 
animals were obtained from Jackson Laboratory and backcrossed 5 generations to yield 
congenic B6 offspring. Apoef l / f l/CSF1R-Cre+/- mice were subsequently bred with 
5xfAD+/- animals to generate experimental animals. All rodent experiments were 
performed in accordance with animal protocols approved by the Institutional Animal 
Care and Use Committee at the University of California, Irvine. The 5xfAD174 mouse 
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model has been previously described in detail. At the end of treatments, mice were 
euthanized via CO2 inhalation and transcardially perfused with 1X phosphate buffered 
saline (PBS). For all studies, brains were removed, and hemispheres separated along 
the midline. Brain halves were either flash frozen for subsequent biochemical analysis 
or drop-fixed in 4% paraformaldehyde (PFA (Thermo Fisher Scientific, Waltham, MA)) 
for immunohistochemical analysis. Fixed half brains were sliced at 40 μm using a Leica 
SM2000R freezing microtome.  
 
Confocal Microscopy: Immunofluorescent labeling was performed on mouse and 
human brain sections following a standard indirect technique as previously described180. 
Mice were perfused with PBS prior to tissue fixation, followed by tissue sectioning to 
produce 40 µm thick floating sections. Primary antibodies and dilutions used are as 
follows: anti-ionized calcium-binding adapter molecule 1 (IBA1; 1:1000; Wako, Osaka, 
Japan), anti-Apolipoprotein E (ApoE; 1:100; Abcam), and anti-glial fibrillary protein 
(GFAP; 1:1000; Abcam). Thioflavin-S (Thio-S; Sigma-Aldrich) staining was carried out 
as previously described181. Total microglia and plaque counts/volumes were obtained by 
imaging comparable sections of tissue from each animal at the 20X objective, at 
multiple z-planes, followed by automated analyses using Bitplane Imaris 7.5 spots or 
surfaces modules, respectively.  
 
Statistics: Every reported n is the number of biologically independent replicates. 
Immunohistological data were analyzed using a two-tailed independent-samples t-test 
(5xfAD vs. 5xfAD + PLX5622 or 5xApoE vs. 5xApoECC) in GraphPad Prism Version 7 
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Figure 3.1: ApoE immunoreactivity is absent from plaques and microglia with PLX5622 
treatment. A, Immunolabeling of tissue from 7-month-old 5xfAD animals for microglia (IBA1 in 
green), ApoE (in red), and stained for dense-core deposits (Thio-S in blue), showing high 
immunoreactivity of ApoE in plaque cores and microglia. B-E, Representative images of the cortex 
(B, C) and thalamus (D, E) from 7-month-old 5xfAD animals treated with control diet or PLX5622 
immunolabled for ApoE (in red) and microglia (IBA1 in green), and stained for dense-core deposits 
(Thio-S in blue). F, ApoE immunoreactivity is reduced in plaque cores of treated 5xfAD animals 
relative to untreated 5xfAD mice in the cortex (p<0.001) and thalamus (p<0.001). Two-tailed 
independent t-test; n = 7-10 for 5xfAD, n = 7 for 5xfAD+ PLX5622. Statistical significance is denoted 
by *p<0.05, **p<0.01, and ***p<0.001. Error bars indicate SEM. 
 
(La Jolla, CA). Symbols denote significant differences between groups: *p<0.05, 
**p<0.01, and ***p<0.001. Statistical trends are accepted at p<0.10 (#). Data are 
presented as raw means and standard error of the mean (SEM). 
 
RESULTS 
Microglial ApoE facilitates plaque formation in 5xfAD mice: 
Previous reports describe the coaggregation of ApoE with Aβ fibrils in both plaques and 
vascular pathology82,242. Consistent with this, ApoE immunoreactivity was apparent 
within dense core plaques, but also in cellular processes surrounding the cores (Fig. 
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3.1A). In this study, colocalization of ApoE with the microglia/myeloid marker IBA1 
revealed that these ApoE+ processes were indeed microglial (Fig. 3.1A). These data 
provide evidence that microglia surrounding plaques contain ApoE, potentially indicating 
a unique role for microglial-expressed apoE in the immune response to AD pathology80. 
Examination of ApoE immunoreactivity in microglia-devoid 5xfAD mice showed a strong 
reduction in ApoE+ staining in microglial processes surrounding dense core plaques, as 
expected, as well as in the plaque cores themselves. We quantified ApoE 
immunoreactivity in Thio-S+ dense-core plaques in the cortex (Fig. 3.1B, C) and 
thalamus (Fig. 3.1D, E), and found a 50-70% reduction in plaque core ApoE (Fig. 3.1F). 
Thus, microglia surrounding fibrillar plaques appear to be a significant source of plaque-
associated ApoE, consistent with recent findings showing an upregulation of ApoE in 
specifically plaque-proximal microglia82,119. 
To further investigate the role of microglial ApoE signaling in facilitating plaque 
formation in AD, we generated a mouse model in which ApoE expression is specifically 
and constitutively excised from microglia/myeloid cells (i.e., under the CSF1R promoter) 
in 5xfAD animals via a Cre-lox system (5xApoECC; Fig. 3.2A). To evaluate the 
efficiency with which Cre recombines loxP sites under the CSF1R promoter, we crossed 
a CSF1R-cre animal to a Rosa26YFP reporter mouse, generating offspring that express 
YFP in microglial progeny and found a ~76% recombination efficiency as measured by 
%IBA1+ cells expressing YFP (Fig. 3.2H), highlighting the efficiency of cre 
recombination of the floxed Apoe alleles. Immunohistochemical analysis of 4-month-old 
5xApoE and 5xApoECC animals revealed that ApoE expression is predominantly 
restricted to GFAP+ astrocytes in both groups (Fig. 3.2C, D), suggesting that significant 
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upregulation of microglial ApoE occurs later in the disease process, as shown by our 
initial immunohistochemical assays for ApoE in 7-month-old animals (Fig. 3.1A) and 
recent reports82,119. However, analysis of dense core plaques in the subiculum of 4-
month-old 5xApoECC mice (Fig. 3.2C-F) revealed a ~30% reduction in both plaque 
number (Fig. 3.2G) and volume (Fig. 3.2H) relative to 5xApoE controls. Collectively, 
Figure 3.2: Microglial ApoE contributes to plaque formation. A, Schematic of 5xfAD+/-
/ApoEfl/fl/CSF1R-cre+/- (5xApoECC) mouse model of microglial knockout of ApoE in 5xfAD mice and 
experimental design. B, Cortical image of a CSF1R-cre+/- animal crossed to a Rosa26-YFP reporter 
line, demonstrating a 76% recombination efficiency in microglia. C, D, Images of subicula stained for 
dense-core plaques (Amylo-Glo in green). E, F, Zoomed images of 5xApoE and 5xApoECC animals 
stained for dense-core plaques (Amylo-Glo in green), microglia (IBA1 in red), astrocytes (GFAP in 
blue) and ApoE (in yellow). G, H, Quantification of Amylo-Glo staining reveals a reduction in plaque 
number (p=0.009) and volume (p=0.027), respectively, with knockout of microglial ApoE in 5xfAD 
mice. Two-tailed independent t-test; n = 7 for 5xApoE, n = 7 for 5xApoECC. Statistical significance is 
denoted by *p<0.05, **p<0.01, and ***p<0.001. Error bars indicate SEM. 
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these findings provide further evidence that microglial activity facilitates the formation of 
plaques in AD and that this process is mediated in part by microglia-specific production 
of ApoE.  
 
DISCUSSION 
Our previous work has established that the absence of microglia in 5xfAD results in 
diminished plaque formation and altered pathological deposition (i.e., shifting from the 
parenchyma to vasculature). To expand upon these findings, we next sought to 
determine the mechanism underlying this observation. In line with data from chapter 
one (i.e., microglia elimination subsequent to plaque deposition) and results from 
chapter two (i.e., microglial ablation prior to plaque onset), modulation of ApoE signaling 
after the emergence of plaques has no effect, whereas intervening prior to the period of 
plaque deposition altered Aβ accumulation225,241. Notably, the manipulation of ApoE in 
AD mouse models phenocopies the absence of microglia (i.e., appearance of CAA 
instead of plaques242-244,250). In the extended absence of microglia in 5xfAD mice, we 
find a lack of ApoE within plaque cores, suggesting a shared pathway between 
microglia, ApoE, and Aβ that contributes to plaque formation. In line with these findings, 
a recent study demonstrated that plaque-associated microglia upregulate ApoE 
expression82,83 and contribute to the coaggregation and accumulation of ApoE in 
plaques82. Moreover, it was shown that microglia take up ApoE-Aβ complexes via 
TREM2256, hypothesizing that ApoE facilitates Aβ uptake and that microglial clearance 
of Aβ protects against plaque deposition. However, we contend that ApoE-Aβ 
complexes are an important convergence point by which Aβ is internalized by microglia, 
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ultimately resulting in plaque seeding. In support of this, ApoE knock-out models exhibit 
reduced Aβ pathology/plaques - not enhanced plaque burden - providing further 
evidence that plaque formation occurs in an ApoE-dependent fashion. Here, we extend 
these findings further by investigating a pathophysiological convergence between ApoE 
and microglia that contributes to plaque formation, given the pathological similarities 
between microglia- and ApoE-null mice. To explore this further, we selectively excised 
Apoe from myeloid cells in 5xfAD mice, revealing reductions in plaque number and 
volume without fully preventing the formation of plaques, as observed in the cohort of 
5xfAD mice depleted of microglia for six months in chapter two. While ApoE expression 
is primarily astrocytic in 5xACC animals, microglia are reported to regulate astrocyte 
activation in AD64, which may play a role in the observed reduction in plaque burden. 
Thus, our data provide evidence that microglia-derived Apoe plays an important role in 
plaque formation but does not represent the single mechanism by which microglia 
promote the formation of A plaque pathology.  
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DISSERTATION CONCLUDING REMARKS 
Currently, treatment options for AD are limited to symptomatic relief, rather than 
targeting initiating factors that drive disease onset and progression. For this reason, no 
AD treatment has proven effective at altering the course of disease-related pathology or 
cognitive decline. The lack of disease-modifying therapies presumably stems from the 
underlying and causative disease mechanisms in AD remaining elusive, despite 
numerous attempts to identify such mechanisms. Due to long-standing support of the 
amyloid cascade hypothesis, A-targeting therapies aimed at reducing the production or 
increasing the clearance of A have been the object of several clinical trials. However, 
these compounds have all failed in the clinic, indicating that A is not the pathogenic 
factor driving cognitive decline in AD. Although a possible pathogenetic role of Aβ 
cannot be completely ruled out at present, the breadth of evidence accumulated to date 
points to a waning of the amyloid cascade hypothesis, leading to renewed efforts of the 
scientific community to identify the true culprit(s) of Alzheimer’s disease. Recently, 
neuroinflammation, of which a chronic form is observed in AD, has gained considerable 
research interest, stemming from GWAS findings that highlight variants in myeloid 
genes as a significant risk factor for AD development. Thus, it is only recently that 
research has begun to understand and appreciate the multitude of roles myeloid cells 
play within AD, including their contribution to disease pathology. 
In the CNS, microglia are the resident myeloid cell that perform immune surveillance 
and supportive functions to maintain CNS homeostasis. From development to 
adulthood, microglia are crucial in shaping neuronal connectivity through refinement of 
extranumerous synapses and neurons, thereby establishing and preserving a functional 
103 
 
network, as well as supporting neuronal health through the release of neurotrophic 
factors. In addition to their roles in the healthy brain, microglia have been shown to exert 
dichotomous and differential functions in the AD brain, including A degradation and 
seeding, neurotoxicity, and synaptic degeneration. Thus, the ways in which microglial 
function changes across the spectra of disease progression (i.e., preceding overt 
pathology, early pathogenesis, and advanced pathology) that ultimately culminates in 
the development of AD remains elusive. As neuroinflammatory processes mediated by 
microglia are complex and multifaceted, much consideration is required regarding the 
modulation and management of this process. In support of this and prior to my 
admittance into graduate school, we demonstrated that microglial depletion in a model 
of hippocampal neuronal lesion resulted in diverging effects depending upon insult 
phase; acute microglial responses were crucial for beneficial post-lesion outcomes, 
whereas chronic microglial activation exacerbated neuronal loss and cognitive 
functioning. Thus, for my dissertation, I sought to investigate the various roles of 
microglia over the spectrum of the most prevalent neurodegenerative disease, AD.  
In the first chapter of my dissertation, I determined that microglia in the AD brain are 
dependent on CSF1R signaling for their survival, and through this, was able to ascertain 
the effects of one-month of microglia depletion on AD pathology dynamics under 
severe/advanced pathology conditions. Using CSF1R inhibitors to eliminate microglia 
for one month in 10-month-old 5xfAD mice, I found a recovery of contextual memory, a 
reversal of dendritic spine loss, and prevention of neuronal loss, and yet no changes on 
A levels or plaque deposition. These data highlight the largely detrimental roles of 
microglia in the aged AD brain, predominantly carried out by plaque-distal microglia. To 
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expand upon these findings, I next set out to explore the contribution(s) of microglia to 
plaque formation in the initial stages of the disease, which is described in the second 
chapter of my dissertation. Importantly, this requires prolonged depletion of microglia 
throughout the plaque-forming period, which is only achievable using CSF1R inhibitors. 
To that end, I administered PLX5622 to 5xfAD mice at 1.5 months of age to deplete 
microglia for ~6 months. With the elimination of microglia, we uncovered critical roles of 
these cells in plaque formation and growth, as well as modulating hippocampal neuronal 
gene expression in response to A pathology. Thus, contrary to the current body of 
literature pointing to microglial dysfunction as a driving factor in plaque onset, it appears 
that plaque formation is a physiological activity of microglia and may be the benign 
product of a deeper pathological process. However, subsequent to plaque formation, 
microglia mitigated toxicity to nearby neurons by compacting A fibrils into dense 
deposits, highlighting the contrasting roles of microglia in early AD. Collectively, these 
results point to microglia as critical and causative in the development and progression of 
multiple facets of AD. Based on the findings of diminished plaque formation, I 
hypothesized that microglial functions in plaque formation are dependent on ApoE, 
given the parallels between pathology in microglia- and ApoE-null mice. To that end, I 
created a mouse model that expresses floxed Apoe alleles under a transgenic CSF1R 
promoter, effectively knocking out ApoE expression from myeloid cells without affecting 
the endogenous CSF1R locus. In line with my hypothesis, knockout of the Apoe gene 
from microglia/myeloid cells reduced plaque numbers and volumes, indicating that 
microglial ApoE is at least partially involved in the formation of plaques in 5xfAD mice. 
However, as A plaques were observed in 5xfAD animals lacking microglial ApoE 
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signaling, this suggests that other cellular sources of ApoE or other signaling pathways 
altogether contribute to plaque formation in AD. 
Collectively, these data strengthen our understanding of microglial influences on 
neuronal health and protein aggregate clearance the AD brain, reveal diverging, 
disease/pathology-dependent functions of these cells, and identify a unique pathway 
involved in microglia-mediated plaque pathogenesis. These findings highlight the 
significance of microglia in the development of AD, and with hope, will accelerate the 
development of disease-modifying therapies that target and modulate microglial 
function. 
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